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Abstract 
Osteoarthritis (OA) is a type of joint disease involving cartilage and its 
underlying bone.  It is the leading cause of disability, especially in developed 
countries, where the elderly account for a large and growing percentage of the total 
population.  It occurs when the cartilage, the tissue covering the ends of long bones, 
breaks down.  The cartilage has no vasculature and, therefore, has a very limited self-
repair capacity.  As a result, the tissue’s effort to repair its own injury results in 
degeneration and evolution into an osteoarthritic lesion, rather than healing.  Current 
strategies for articular cartilage treatment have rather temporary effects, and, joint 
replacement is inevitable.  Among various surgical techniques, cell-based tissue 
engineering methods appear to be the most promising.  In autologous chondrocyte 
implantation (ACI) or matrix-assisted chondrocyte implantation (MACI) a cell 
suspension is transferred to the defect.  Studies show that these methods enhance 
cartilage regeneration, however, the newly formed repair tissue is very fragile, and 
further improvement in these techniques or the development of new strategies are 
required.  To address this problem, a number of research groups have investigated 
(used) decellularized cartilage matrix as a bioscaffold for seeding cells to transfer a 
more mature engineered tissue into the defect, although cell infiltration through the 
cartilage’s dense extracellular matrix (ECM) is a real challenge.  Therefore, it was 
hypothesized that the provision of micron-sized cartilage matrix would increase the 
efficiency of cellular infiltration, and would enhance the functionality of 
decellularized cartilage matrix as a scaffold material.   
Human articular cartilage taken from macroscopically healthy parts of 
osteoarthritic joints was lyophilized and pulverized into particles with an average 
diameter of 2 µm, which we termed “cartilage dust (CD).  Then, CD particles were 
incorporated into chondrocyte pellets.  The resulting CD-supplemented cartilage 
constructs were compared with cell-only constructs after 2 weeks in vitro culture, 
and after 4 weeks in vivo implantation in immune deficient mice.  Constructs were 
analysed macroscopically, and through measurement of glycosaminoglycan (GAG) 
production, chondrogenic and osteogenic gene expressions, histology, and antibody 
immune-localization. 
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In vitro experiments demonstrated that the cartilage dust was reasonably well-
integrated with cells in the de novo cartilage-like tissue.  Compared to cell-only 
pellets, CD-containing constructs produced almost twice as much GAG in vitro, and 
expressed higher amounts of chondrogenic genes, but also exhibited an upregulation 
of osteogenic genes.  CD-supplemented constructs remained stable when 
subcutaneously implanted in mice for 4 weeks, while the majority of cell-only 
constructs were degraded or lost.   
In summary, incorporation of CD particles with chondrocytes appears to be a 
viable strategy to increase the cartilage-like matrix content in the short-term, and the 
CD matrix appears to integrate into the de novo tissue in the long-term. 
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Chapter 1: Literature Review 
1.1 BACKGROUND AND CONTEXT 
 
Cartilage has no vasculature and, therefore, has a very limited self-repair 
capacity [1].  In fact, a cartilage lesion is more likely to degrade further forming an 
osteoarthritic lesion, rather than spontaneously repair [1].  In addition to influencing 
quality of life, articular joint disorders impose a heavy burden on health systems [2], 
particularly in countries with aging populations [3].  In Australia the economic 
burden of joint inflammatory diseases, has been estimated to be $24 billion per year 
[4].  This includes the cost of medical treatments, as well as the factors that indirectly 
influence the cost, such as leaving work because of the disease symptoms or the time 
spent seeking and receiving treatment [5].   
Articular cartilage injuries can potentially be debilitating.  Different aetiologic 
factors, such as congenital abnormalities, traumatic damage, tumours, and 
degenerative processes related to age may lead to these defects [6].    Since this type 
of cartilage is constantly under pressure, especially in major joints such as the knee 
and hip [7], its maintenance is critical.  Normally, the old or damaged components 
should be degraded (catabolism) and, subsequently, replaced by new ones 
(anabolism).  The balance between this catabolic and anabolic activity can be 
compromised  as the result of various factors, such as aging, resulting disrupted 
tissue homeostasis and increased vulnerability to damage [8].  Cartilage is gradually 
lost to the point that the underlying bone becomes exposed in some load-bearing 
areas of the joint.  This leads to joint stiffness and pain which, in turn, results in 
movement limitation and, therefore, weakening of the joint muscles.  Biochemical, 
biomechanical, or genetic factors may accelerate or decelerate this process, but are  
unlikely to stop or reverse it [9].  Since osteoarthritis (OA) is the most probable and 
prevalent of cartilage and joint disorders [10], OA may be mentioned as joint 
diseases’ equivalent in this thesis.   
Various surgical interventions have been developed for the treatment of 
articular cartilage diseases, including arthroscopic methods, soft tissue/osteochondral 
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grafts, as well as cell-based therapies such as autologous chondrocyte implantation 
(ACI).  Arthroscopic methods are based on provoking endogenous repair responses 
through bleeding [11, 12].  Despite the potential alleviation of pain and functional 
improvement, the repaired tissue is not structurally or biomechanically similar to 
natural joint cartilage tissue [13], and in most cases the degenerative process 
progresses until the replacement of the whole or part of the joint becomes necessary.  
Tissue engineering and regenerative treatments as novel treatment options appear to 
be superior substitutes for the traditional methods in effectively treating articular 
cartilage defects [9, 14].   
Autologous chondrocytes implantation (ACI) is the only cell-based tissue 
engineering therapy which has gained the United States Food and Drug 
Administration’s (FDA) approval [15].  In this procedure chondrocytes are harvested 
from a non-load bearing location on the joint, isolated and expanded in culture.  The 
expanded cells are then used to repair the primary defect.  This procedure has some 
disadvantages, including the possibility of de-differentiation of the harvested 
chondrocytes [16], limited donor tissue availability, and the necessity for preliminary 
surgery and tissue biopsy to recover the chondrocytes [17].  To address some of these 
limitations, one solution may be to use bone marrow-derived mesenchymal stem 
cells (BM-MSCs) instead of autologous chondrocytes, as they can be harvested in 
large amounts by a simple method, expanded in vitro, and are capable of undergoing 
chondrogenic differentiation after in vitro expansion [18]. While promising, the 
feasibility of this approach requires that in vitro chondrogenic differentiation 
techniques of MSCs be improved [16].  Achieving an optimum and reliable 
technique for chondrogenic differentiation in which MSCs demonstrate a stable 
chondrogenic phenotype in vivo without undergoing hypertrophic changes is 
currently a challenging issue that requires more research [19, 20].   
Significant advancements in tissue engineering have been achieved through the 
use of biological scaffolds derived from decellularized tissues.  A variety of tissues, 
for example skin [21], heart valve [22], and trachea [23] can be the source of these 
ECM-derived materials.  Comprehensive research has been done on the matrices 
derived from urinary bladder and small intestine subcutaneous (SIS) [24].  Naturally 
occurring ECM plays many roles.  Generally, it provides structural support, 
facilitates communication among cells, and controls the release of growth factors, 
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just to name a few [25].  Indeed, the ECM possesses the ultimate features of an ideal 
scaffold, as it is produced by the resident cells of a given tissue or organ.  The ECM 
derived from decellularized tissue, therefore, has the potential to guide the host cells 
towards “constructive remodelling” rather than scar formation, a mechanism which is 
yet to be fully explored [26].   
Cartilage is an ECM-rich tissue in which cells occupy less than 5% of its 
volume [12].  Therefore, the concept of using decellularized tissue appears ideal for 
this tissue [27].  However, its high density makes the initial decellularization and 
consequent repopulation challenging [28, 29].  There have been a growing number of 
studies that investigated various forms of acellular cartilage to produce cartilage 
constructs, for example pieces [30], sheets [31],or cross-linked powder [32, 33].  
Although it has been reported that cartilage cells successfully bind decellularized 
cartilage pieces together [30], migration of the cells through the dense cartilage 
matrix and, consequent repopulation of the matrix followed by regeneration remains 
a real challenge.  In particular, efficient repopulation of cartilage matrix pieces larger 
than 10 µm is hard to achieve [34].  Based on this observation, it was reasoned that 
the integration of microscopic particles of decellularized cartilage matrix with 
cartilage cells could address this problem.   
 
1.2 HUMAN ARTICULAR CARTILAGE 
 
Articular cartilage is a specialized type of connective tissue that coats the ends 
of long bones in synovial or diarthroidal joints.  It functions to absorb shocks, 
distribute loads, and provide a lubricated surface for near frictionless movements of 
the joint [35].  Unlike other types of connective tissues, articular cartilage contains 
no blood vessels and, therefore, has a limited self-repair capacity [36].  It also lacks 
nerves [37], which often prevents patients from becoming aware of the damage until 
it is severe.  Thickness of articular cartilage varies in different joints.  For example, 
the mean human cartilage thickness has been found to be in the range of 1-1.62 mm, 
1.35-2.0 mm, and 1.69-2.55 mm, in ankles, hips, and knees, respectively [38].   
Articular cartilage is coated with synovium instead of vascular perichondrium.  
As a result the exchange of nutrient supplies and waste products occurs by diffusion 
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through synovial fluid, which is confined only to the surface zone [39].  For this 
reason, the fluid convection resulting from functional movement of the joint is 
critical for deeper zone cell vitality.  The dependence on joint motion-induced 
convection and the considerable distance between the small blood vessels of the 
synovium and the chondrocytes residing in the deeper zones demonstrates the limited 
nutrient supply within cartilage [40].  
Understanding the development of a normal joint is crucial and may aid the 
successful regeneration and repair of the tissue, and will be reviewed briefly in the 
following section. 
 
1.2.1 Development 
 
Unlike mature, low cell density cartilage, the growing tissue has a high number 
of cells in its early stages of development [41].  Over the process of the joint 
development, the immature cartilage grows through either increasing the volume 
(interstitial growth) or surface (appositional growth) of its ECM [42].  The 
development of the joint in terms of the skeletogenesis and joint formation, as well as 
the role of growth and differentiation factors will be briefly discussed in the 
following sections. 
 
Skeletogenesis and Joint Formation 
 
In the developing foetus, mesenchymal stem cells (MSC) from three separate 
origins, move to areas of the future skeleton and settle down in a dispersed manner.  
These progenitor cells secrete a temporary ECM including collagen types I and IIA, 
hyaluronan, fibronectin, tenascin-C, neuralcadherin (N-cadherin), and neural cell 
adhesion molecule (N-CAM), which is a requisite for the aggregation and 
differentiation of these cells.  Subsequently, MSCs gather together to form 
condensed groups of cells [43-46].  Indeed, skeletogenesis begins through the 
development of an uninterrupted condensation of apparently identical mesenchymal 
cells to form rod-shape structures associated with long bones, known as “anlagens” 
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[47].  The close contact of cell surfaces, coupled with released biological signals, 
results in the transformation to spherical chondrocytes (differentiation stage) and 
subsequent ECM synthesis including collagen types II, IX, XI, and aggrecan [43-46].  
In the following step, some differentiated chondrocytes form a cartilaginous skeletal 
template, in the middle of which cartilage is eventually replaced by bone through a 
process termed “endochondral ossification”.  Other chondrocytes maintain their 
chondrogenic phenotype (Figure 1.1).  The resulting tissue is a long bone flanked at 
each end by articular cartilage [47].  
With further morphogenesis and differentiation, the joint becomes mature and 
ready to function [48].  This process includes complex mechanisms that determine 
the precise location of the future joint in the uninterrupted condensation of cells.  The 
Homeobox (HOX) genes appear to play a key role in this process [49].  The 
emergence of the so called “interzone” indicates the first sign of joint formation.  The 
interzone is composed of closely packed mesenchymal-like cells, which demarcates 
the adjacent cartilaginous rudiments.  In contrast to mesenchymal cells in the sites of 
future bone, interzone cells are linked to each other through gap junctions [50].  As 
development proceeds, cavitation occurs within the interzone, resulting in the 
formation of the synovial space.  The interzone differentiates into two 
perichondrium-like layers that sheathe the articular surfaces, and one intermediate 
layer that forms a synovial cavity.  The perichondrium consists of a layer of 
mesenchymal cells that sheathe cartilage anlagen, and produce type I collagen, the 
primary protein in bone matrix [51].  
A “growth plate” is located at each end of the cartilage template.  It is characterized 
by different zones in which the zonal chondrocytes possess distinct molecular and 
morphological features (see Figure 1.1).  The proliferative zone, which is adjacent to 
the articular cartilage, consists of round and proliferative periarticular chondrocytes.  
These cells have the greatest proliferation capacity within cartilage.  The next zone 
contains flat and columnar chondrocytes that exhibit markers of early maturation.  
Pre-hypertrophic and hypertrophic chondrocytes reside in the next two zones 
respectively [52].  Figure 1.1 illustrates a comprehensive summary of the events that 
occur during endochondral bone ossification and articular cartilage development 
[52]. 
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Figure 1.1. Cellular events and molecular markers of chondrogenesis, chondrocyte 
differentiation, and AC development and maintenance. 
(A) Model of endochondral bone development beginning with mesenchymal cell 
condensation (i); chondrocyte differentiation and development of the cartilage 
template (ii); chondrocyte maturation and hypertrophy (iii); separation of cartilage 
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growth regions, vascular invasion, and initiation of both cortical and trabecular bone 
(iv); and finally generation of the secondary center of ossification that separates AC 
and GP cartilage during postnatal bone development (v). MC, marrow cavity; 2°, 
secondary center of ossification. Red lines mark the vasculature, and yellow 
coloration marks mineralized bone. Black box outlines AC region magnified in B. 
(B) Graphical representation of the distinct cellular zones in postnatal AC. IZ, 
intermediate zone; RZ, radial zone; TM, tide mark; ZCC, zone of calcified cartilage; 
SB, subchondral bone; M, marrow. Vertical lines indicate zones of gene expression. 
(C) Model outlining the process of chondrogenesis and chondrocyte differentiation. 
Important markers at each stage of chondrocyte differentiation are listed below the 
stage at which the genes are expressed. Superscripts indicate the level of gene 
expression [52]  
Image reprinted here by permission of the American Society for Clinical 
investigation (see Appendix A). 
 
 
Articular chondrocytes have significant differences relative to “transient” 
chondrocytes found in the growth plate and embryonic skeleton.  For example, 
hypertrophic chondrocytes are phenotypically dissimilar to proliferating 
chondrocytes since they express type X collagen instead of type II [51].  Growth 
plate chondrocytes are characterized by a highly dynamic phenotype.  They 
proliferate, become hypertrophic, mature, die, and finally are replaced by osteoblasts 
[47, 53-55].  In contrast, once formed, articular chondrocytes maintain their 
phenotype for most of the organism’s life-time [56].  However, they may lose their 
function because of aging, or become hypertrophic due to osteoarthritis [55, 57].  
The mechanism by which these cells normally maintain their stable hyaline 
phenotype and avoid maturation and hypertrophy is still not clear and represents a 
vast field of active research [58-67].  
Whilst there are obvious differences in the behaviour of various chondrocyte 
populations, it can be challenging to differentiate the population.  It has been 
reported that a microtubule-associated protein, doublecortin X-linked (DCX), is 
found only in articular chondrocytes.  It is not expressed in the growth plate 
chondrocytes or in the middle layer of interzone which gives rise to synovium. 
Therefore, this specific marker can be employed to identify articular chondrocytes.  
DCX can also be used to assess the quality of engineered tissue in terms of whether 
MSCs are efficiently differentiated into articular chondrocytes [68]. 
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Different patterns of gene expressions happen over the complicated processes 
of articular cartilage development and endochondral ossification that  are not yet 
fully appreciated and nor is their precise interaction [69].    In the following section 
some of the major discoveries related to this morphogenic process will be briefly 
reviewed. 
 
 
The Role of Growth and Transcription Factors in Joint Development 
 
Growth/differentiation factor-5 (GDF-5)  
 
During the condensation stage, growth and differentiation factor 5 (GDF-5), a 
member of the bone morphogenic protein (BMP) family which is also known as 
cartilage derived morphogenic protein-1 (CDMP1), stimulates differentiation, but 
later it is expressed only in the interzone [53, 70].  It has been shown that interzonal 
cells which express GDF-5 are the origin of articular chondrocytes, while growth 
plate chondrocytes are derived from GDF-5 negative cells in the bulk of the closely-
packed mesenchymal cells from which both cell populations are derived [71, 72].  As 
development progresses, GDF-5 is found in the distal convex side of the opposing 
joint surfaces, but not in the concave side [54].  GDF-5 provokes osteogenic 
differentiation and expression of vascular endothelial growth factor A (VEGF-A) in 
rat bone marrow-derived mesenchymal stem cells in vitro [73].  GDF-5, therefore, 
has an important role in the promotion of joint development during skeletogenesis, 
but after that, its expression probably encourages angiogenesis and ossification in 
cartilage [73].  This might indicate that GDF-5 enhances in vitro chondrogenesis if 
used early in the MSC-to-chondrocyte culture.  Conversely, since it has been 
observed that the MSC population has begun to mature in vitro, perhaps the GDF-5+ 
cell population needs to be selected.  
 
Wnt-14 (Wingless-related integration site) 
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Microsurgically-isolated interzonal cells have been reported to express Wnt-14, 
GDF-5, and collagen IIA (Col IIA) [74].  After culturing these cells in a medium 
containing serum for a few days, they differentiated into chondrocytes.  Also, it has 
been found that over expression of Wnt-14 through retroviruses resulted in a failure 
of these cells to differentiate and retention of their mesenchymal appearance and 
markers, as well as mesenchymal adhesion and migration features [72].  This 
observation indicates that Wnt-14 may have anti-chondrogenic properties that inhibit 
mesenchymal cells in the interzone from differentiating into chondrocytes.  Further 
investigation is needed to understand how interzonal cells escape from the effect of 
Wnt-14 and mature into articular chondrocytes.  This would provide an important 
insight that could be utilized to stimulate endogenous repair.   
 
Runt-related transcription factor-2 (Runx2) 
 
Throughout skeletogenesis, runt-related transcription factor-2 (Runx2) is recognized 
as the earliest transcriptional indicator of osteogenic differentiation [75, 76].  It is 
temporarily expressed in prehypertrophic chondrocytes along with other factors.  It is 
highly expressed in the perichondrium, and has been shown to have an important role 
in the anti-hypertrophic feature of perichondrium [69], implying that it may have 
opposing actions in chondrogenesis, depending on the time and location of its 
expression. 
 
Parathyroid hormone-related peptide (PTHrP) 
 
Parathyroid hormone-related peptide (PTHrP) is a member of the parathyroid 
hormone (PTH) family.  However, whilst PTH circulates throughout the body, 
PTHrP is secreted and functions locally in tissues.  Both PTH and PTHrP share a 
common receptor, and low and high levels of this receptor have been detected in 
proliferating and pre/early hypertrophic chondrocytes respectively [51].  It is 
hypothesized that the interzone of cartilage tissue modulates chondrocyte maturation 
by secreting PTHrP.  Critically, PTHrP has been shown to delay or prevent 
hypertrophy in chondrocytes in vivo and in vitro [77, 78].  
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In a study by Kim et al. BM-MSCs and adipose tissue-derived MSCs (AT-
MSCs) were cultured in chondrogenic induction medium in vitro for 28 days.  At day 
14, pellet cultures were treated with different doses of PTHrP for another 14 days.  
Hypertrophy-related genes were significantly diminished, while chondrogenic 
markers were considerably enhanced in PTHrP treated cultures.  The authors’ 
conclude that PTHrP inhibits hypertrophy and also promotes chondrogenesis in both 
BM-MSCs and AT-MSCs in a dose-dependent manner [79].  PTHrP and PTH may 
be critical factors for future MSC based cartilage engineering to prevent hypertrophy. 
 
Indian hedgehog (Ihh) and PTHrP - Ihh  
 
Indian hedgehog (Ihh) is a signalling molecule that is secreted by 
prehypertrophic and maturing chondrocytes.  Ihh could regulate interzone function, 
as its target genes, Gli2 and Gli3, are detected in the interzone [80].  Therefore, it 
may be one of the factors that preserves the characteristics of interzone mesenchymal 
cells, and could be used to facilitate the generation of zonal cartilage tissues. 
Vortcamp et al. were the first group to report the ability of Ihh to postpone 
hypertrophy in vitro by provoking the production of PTHrP.  They achieved this 
through virally-transduced over-expression of sonic hedgehog gene in chicken 
chondrocytes, and then again in vivo through the addition of hedgehog protein to 
mouse limbs [78].  Chondrocytes residing near the ends of long bones produce 
PTHrP which cause chondrocytes residing in the proliferating zone to continue 
proliferation.  Chondrocytes at a sufficient distance such that they are not affected by 
the PTHrP signal, cease proliferation and start to produce Ihh.  Ihh, in turn, through a 
negative-feedback loop, stimulates the chondrocytes residing near the ends of long 
bone to produce PTHrP [51].  Ihh also influences perichondrial cells to change into 
osteoblasts [81].  Therefore, it appears that Ihh is necessary for regulation of 
proliferation, maturation rate and ossification of chondrocytes. 
 
 
Vascular endothelial growth factor (VEGF) 
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The effect of hypoxia on the activation of angiogenic pathways in normal 
articular cartilage is unclear.  Given that cartilage is avascular and hypoxic, and the 
major stimulus for angiogenesis is hypoxia, it is likely that there are anti-angiogenic 
factors, and/or other factors which inactivate angiogenic pathways [82].  Vascular 
endothelial growth factor (VEGF) plays an important role through initial cartilage 
development [83], whilst in mature tissue its activity must be blocked.  Again, in 
more mature hypertrophic tissue VEGF plays an important role in cartilage 
calcification.  Hypertrophic chondrocytes secrete VEGF and display the VEGF 
receptor (VEGFR).  Since chondrocytes express VEGF receptor-2 (VEGFR-2), it has 
been hypothesized that VEGF can have an autocrine effect that switches from 
chondrogenic to osteogenic phenotype [84, 85].  This hypothesis is supported by 
experiments where blocking VEGF with antibodies delayed chondrocyte apoptosis 
and expanded the growth plate due to an increased number of hypertrophic 
chondrocytes [85]. 
In OA, the level of VEGF in synovial fluid is 60 times higher than that of 
normal joints [86].  It has been proposed that reactive oxygen species (ROS) play an 
important role in VEGF and VEGFR production in osteoarthritic chondrocytes [86].  
If this is true, then high concentrations of ascorbic acid utilized in chondrogenic 
medium may need to be considered as driving redox signalling and subsequent 
VEGF expression [87].  
 
Transforming growth factor-β (TGF-β)  
 
Transforming growth factor- β (TGF-β) is a commonly utilized growth factor 
included in in vitro MSC–to–chondrocyte differentiation cultures.  Since TGF-β1 up-
regulates fibronectin gene expression in micromass cultures, it may have a key role 
in MSC condensation [88].  Further, low oxygen in conjunction with TGF-β up-
regulates the expression of N-cadherin, which is known to facilitate micromass 
aggregation.  Compared to TGF-β1, TGF-β2 and TGF-β3 have greater 
chondroinductive capacity in high density pellet cultures of human BM-MSCs, as 
evidenced by a higher expression of a variety of cartilage genes, such as collagen 
type II and aggrecan [89]. 
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Factors from chondrocytes  
 
Cartilage can have a paracrine effect on adjacent tissues or cells in vitro/in 
vivo.  For example, when co-cultured with growth plate chondrocytes, signalling 
factors released from articular chondrocytes inhibited matrix calcification in transient 
chondrocytes [90].  Expression of hypertrophy-related genes in chondrogenically 
differentiated human BM-MSCs in vitro, followed by vascular invasion and 
ossification after subcutaneous implantation in SCID mice is a commonly observed 
outcome.  In contrast, when chondrocytes are implanted in vivo, they display 
resistance to hypertrophy and calcification [91].  In recent studies, human BM-MSCs 
were co-cultured with human articular chondrocytes at a ratio of 4:1 in hyaluronic 
acid (HA) hydrogels [92].  Expression of collagen X, which is an important marker 
of hypertrophy, was significantly reduced in co-cultures compared to control groups 
of pure MSC.  This implies that factors provided by the chondrocytes may help to 
maintain the differentiated phenotype of the MSC.   
In summary, MSC chondrogenesis and maintenance of the chondrogenic 
phenotype is a complex process influenced by a number of factors that are not yet 
fully understood.   
 
1.2.2 Composition 
 
Chondrocytes 
 
Originating from mesenchymal stem/stromal cells (MSC), chondrocytes appear 
to be the only cell types found in mature articular cartilage, occupying only a small 
volume of the tissue (approximately 1%) [93, 94].  Most chondrocytes are spherical 
in shape, and are entrapped individually or in small numbers in fluid filled spaces in 
the ECM, termed lacuna [95].  Chondrocytes reside in mechanically non monotonous 
environments, which depend on viscoelastic properties of their peri cellular matrix 
(PCM) [96].  Some chondrocytes are equipped with cilia, which are thought to 
perceive mechanical changes due to loading which lead to matrix modification for 
load bearing [97].   
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Despite the common name, chondrocytes in every zone of articular cartilage 
have a distinguishable phenotype and transiently maintain this phenotype during ex 
vivo expansion [15].  Although dispersed and low in number, chondrocytes have a 
pivotal role in articular cartilage ECM turn over to maintain tissue structure and 
function [94].   
 
Extracellular matrix (ECM) 
 
ECM is a hydrated and highly organized matrix, specifically structured to 
tolerate biomechanical pressures, minimize joint friction, absorb shock and preserve 
the bone under the cartilage [12].  Hyaline cartilage ECM contains three predominant 
groups of proteins, including collagens, proteoglycans, and noncollagenous proteins 
[17].  Water, collagens, and proteoglycans are the main components of the cartilage, 
with the weight proportion of 7:2:1, respectively [98].  The collagen network, which 
is accountable for tensile strength of the cartilage, predominantly consists of collagen 
type II, and to a lesser extent, collagen types IX and XI [99].   
Proteoglycan monomers basically consist of a core protein to which one or 
more chains of a sulphated glycosaminoglycan (sGAG), mainly chondroitin sulphate 
and keratin sulphate, is covalently attached [98].  Aggrecan and decorin are the major 
types of proteoglycans in the ECM [6].  Monomers are mainly aggregated by a large 
non-sulphated GAG and hyaluronic acid (HA), in the presence of link proteins [100, 
101].  Proteoglycans cannot normally move through the ECM, because they are 
trapped by the collagen fibres.  They aggregate small, negatively charged sulphated 
glycosaminoglycans (sGAG), such as chondroitin sulphate and keratin sulphate [98].  
Given the high proteoglycan content of the ECM, which is enmeshed and 
immobilized by collagen fibres, articular cartilage has a high, fixed, negative charge 
density, which in turn, attracts mobile cations, including K+, Na+, H+, and water [98].  
The high concentration of protons causes the ECM to be more acidic relative to other 
tissues [102-105].   
 
1.2.3 Organization 
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Histologically, articular cartilage consists of four separate regions.  In each 
zone, the direction of the collagen fibres is different [106].  The superficial or gliding 
zone, which comes in contact with synovial fluid, has the greatest collagen and water 
content, and the least aggrecan content.  Collagen fibrils are located parallel to the 
articular surface, and are the thinnest compared to the fibres in middle and deep 
zones [12, 107].  Chondrocytes in this zone produce and secrete specific proteins, 
including proteoglycan 4 (lubricin) and hyaluronan synthase 1 and 2, into the 
synovial fluid, aiding joint lubrication by decreasing friction [108].  The underlying 
region is known as the middle, intermediate or transitional zone.  Being the thickest 
part of the hyaline cartilage, the middle zone contains thicker collagen fibrils, as well 
as a higher proteoglycan content [107].  The third region, or deep zone, contains the 
largest collagen fibrils that run perpendicularly through the lower calcified tissues, as 
well as  columnar-arranged circular chondrocytes [12].  The fourth zone may be 
considered as the last region, which is termed the calcified zone [106] and is 
integrated with the underlying bone. 
 
1.2.4 Mechanical properties 
 
Articular cartilage is a resilient tissue with different thicknesses in various 
joints, and in diverse species.  In humans, for example, it is 1-5 mm thick depending 
on the type of joint [98].  Each joint is designed to tolerate pressures within its 
physiologic tolerance [109, 110].  Femoral condyle has a compressive modulus 
between 4.3 to 13 MPa [38].  One of the main roles of articular tissue is to transmit 
dynamic forces across the joint, which would otherwise cause mechanical damage to 
the underlying bone [98].  Given that the cartilage contains proteoglycans enmeshed 
in the ECM that also possess a high density of negatively charged GAGs, it has a 
very high osmotic pressure, which draws a huge amount of water to the tissue [98].  
The water absorbed into and retained in the ECM readily flows out during the 
loading of the joint, functioning as a shock absorbent for the joint [93].  When the 
joint is not loaded, the cartilage absorbs water until the tensile pressure created in the 
collagen network equilibrates with the osmotic swelling pressure of the tissue [98].  
The tissue’s response to physiological forces depends on its mechanical properties 
under compressive and tensile pressures [98]. 
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1.3 OSTEOARTHRITIS (OA) 
 
Among the various types of joint disorders, OA is the most prevalent.  In a 
study among 20 chronic diseases, OA ranked the second most common in all age 
groups and in both sexes [111], while in another study, 69% of all types of arthritis 
were OA [112].  Although any of the tissues comprising the articular system might 
be involved [113], cartilage damage or loss is the main feature.  OA is most 
commonly found in large joints, and in older generations [114], however, it can also 
develop in younger patients after traumatic injury of a joint [115, 116].   
 
 
1.3.1 Aetiology 
 
The exact cause of OA remains unknown; indeed, OA can be considered a 
disease with complex and various aetiologic factors which have common 
pathological and clinical consequences [8].  Interaction of these factors increases the 
likelihood of its incidence and progression.  Generally, these risk factors can be 
divided into systemic and local or intrinsic factors, both of which can potentially 
either act on a vulnerable joint, or affect joint vulnerability  [117].   
 
 
1.3.2 Prevalence 
 
OA is mainly considered to be a senile disease with the average age of 65 years 
and over, mainly because of its progressive and nearly irreversible nature [118].  
Under 40 years of age, the prevalence of symptomatic OA is less than 1 in 20 (<5%).  
However, the prevalence grows to 1 in 10 men, and 2 in 10 women (10% and 20%, 
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respectively), in the age range of 45-65 years, and  in people 85 years and older, the 
figure rises to 1 in 2 male or female individuals (50%) [119].  However, it could also 
develop in younger patients after traumatic injury to a joint [10].  Any articular joint 
can be a target for OA, although weight-bearing joints, including knee and hip, are 
most commonly affected.  According to a survey in Australia, 100,393 arthroplasties 
with the diagnosis of OA were performed in 2007-08 financial year.  Total knee and 
total hip replacements accounted for 26% and 19% of all OA-related surgeries, 
respectively [120].   
 
1.3.3 Pathology 
 
Current data regarding OA pathology suggests it is a whole joint lesion with a 
complex aetiology, rather than being chondro or osteocentric [121, 122].  Stated 
differently, OA appears to begin and progress in all tissues of the joint, including the 
synovium, cartilage, bone, bone marrow, meniscus, ligaments, muscles, and even the 
infrapatellar fat pad [123].   
Metabolic imbalance influences articular chondrocytes’ phenotype.  
Chondrocytes undergo hypertrophy and terminal differentiation, followed by calcium 
deposition, which raises the tidemark between mineralized and normal cartilage at 
the expense of reducing the thickness of articular cartilage [121, 124].  At the same 
time, subchondral bone undergoes sclerotic changes, defined by increased thickness 
of the cortical plate and the presence of osteophytes, possibly as an adaptive response 
to mechanical forces or effort to repair mechanically induced defect [124].   
Adult chondrocytes have a low metabolic activity [125].  Abnormal 
mechanical pressure or trauma appear to awaken these “dormant” cells to produce a 
wide range of proinflammatory mediators [126], including cytokines, chemokines, 
reactive oxygen species (ROS) [127], as well as lipid-derived inflammatory 
mediators [128].  Release of inflammatory mediators, which is normally observed as 
being produced by macrophages in the presence of infections or injuries, represents 
the effort of chondrocytes to maintain tissue integrity, homeostasis, and 
function[126].  After damaged tissue is removed through proteolytic enzymes, the 
lyses process should be stopped to allow cells to produce new matrix at the site of 
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injury.  There are some factors responsible for turning off the production of tissue-
destructive enzymes while stimulating matrix synthesis [129].  This process of tissue 
remodelling happens to work insufficiently and defectively in patients suffering from 
OA [125].  Ageing-related factors appear to play an important role in this process; 
with senescence, for instance, chondrocytes become less responsive to the growth 
factor stimulation, leading to an imbalance between catabolic and anabolic activities, 
and more loss of matrix [125].  When catabolic activity of chondrocytes is increased 
by the production of proteolytic enzymes, such as matrix metalloproteinases 
(MMPs), aggrecanase, and VEGF, matrix degradation of articular cartilage occurs [7, 
125].  This catabolic hyperactivity results in the disruption of proteoglycans and 
collagen network of the articular cartilage, the main organic components of cartilage, 
and therefore, loss of cartilage function.  The process ends with programed death 
(apoptosis) of chondrocytes and loss of articular cartilage [7, 9, 121, 125].   
Several signalling molecules appear to play key roles in cartilage and bone 
homeostasis.  Hypoxia inducible factor-1α (HIF-1α), for example, is a transcription 
factor which is expressed in low oxygen conditions and has a balancing effect in the 
development and maintenance of articular cartilage [130].  The hypoxic condition in 
joints suffering from synovitis results in HIF-1α over-expression and, subsequently, 
production of several downstream mediators, such as VEGF.  Formation of 
osteophytes in OA joints appears to be related to the angiogenesis effect of VEGF.  
Further, pro-inflammatory mediators, such as interleukin-1 (IL-1) and tumour 
necrotizing factor-α (TNF- α), can directly cause VEGF over-expression [131].   
TGF-β has a key role in both anabolic and catabolic activities of articular 
cartilage, depending on the receptor through which it works.  Attachment of TGF-β 
to alkaline phosphatase 5 (ALK5) receptor activates SMAD2/3 pathways, and leads 
to the expression of tissue inhibitor of matrix proteinase (TIMP) and prevents 
chondrocytes from hypertrophy [122].  In this pathway, therefore, TGF-β protects the 
articular cartilage from degenerative changes.  It may also provide a valuable clue in 
controlling hypertrophy in chondrogenic cultures in vitro.  On the other hand, 
activation of the signaling pathway through ALK-1 receptor turns on SMAD 1, 5, 8 
pathways, and up-regulates matrix metalloproteinase-13 (MMP-13).  The enzyme 
has a well-known effect in cartilage degradation in OA joints.  It has been reported 
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that TGF-β can induce OA changes when it is continuously injected into joint and 
has a key role in formation of osteophytes [122].   
The key role of tumor necrosis factor α (TNF-α) and interleukin-1 (IL-1) in the 
development of OA was discovered many years ago [132].  Synovial fluid distributes 
these factors in the joint, where they produce effects by direct inhibition of cartilage-
specific ECM synthesis, as well as induction of other pro-inflammatory and 
degradative signalling molecules.  Production of IL-10, an anti-inflammatory 
cytokine with chondro-protective effects, has been reported to be increased in OA 
cartilage, representing chondrocytes’ efforts to relieve damage [129]. 
 
1.3.4   Various burdens on patients and the public 
 
Treatment of cartilage defects, and most importantly OA, presents a significant 
challenge that involves a vast portion of society.  Since OA is currently incurable and 
progressive, the existing management or treatment can only reduce the impact or 
slow the progression of the disease and, consequently, improve a person’s quality of 
life [133], rather than cure it.  It is recommended that several strategies are applied 
together, depending on each individual’s needs and expectations, as well as the 
severity of the disease.  Often, besides the patients and their families or carers, a 
huge team of professionals is required for either the treatment or management of OA.  
Therefore, OA is a major public health problem, rather than just a disease [134].   
It is expected that the damaging effects of OA on both patients and societies 
will markedly grow in coming years.  Higher life expectancy, along with factors 
related to changes in lifestyle, for example the global tendency the increasing 
reliance on modern technologies, which can lead to less physical activity and 
epidemic obesity, are likely to further increase the adverse consequences of OA [133, 
135].  Analysis of the US Medicare administrative information collected over 20 
years (1991-2010) showed an increasing propensity toward total knee arthroplasty 
(TKA) among the members of the health fund [136].  Although part of this growth 
was related to the higher number of people covered by Medicare, there was also a 
significant rise in the number of TKAs applied per capita [136].  
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The financial burden of OA has been shown to be substantial, which is 
imposed on patients and their families or guardians, as well as governments, health 
systems, and the community in general.  Part of this cost is directly related to the 
disease, such as expenses for medications, visits by a general practitioner, or surgical 
procedures [137].  The main cost for hospital care of OA patients is considered to be 
for arthroplasty surgery.  Based on the Australian Government Department of Health 
and Ageing estimations in 2007, undergoing a single hip arthroplasty in a public 
hospital and without any complications cost approximately $14,000 [134].  In that 
year, Australian OA patients spent $7.4 million for one non-steroidal anti-
inflammatory drug (NSAID) to manage their disease condition, which also cost the 
government about $36.9 million [120]. 
There are also other factors that indirectly influence the expenditure on OA, 
such as leaving work because of seeking and receiving treatment or early retirement 
[5, 138].  A considerable amount of Australia’s health budget is spent on 
musculoskeletal disorders and arthritis [4].  The economic burden of joint 
inflammatory diseases, including direct and indirect costs, has been estimated to be 
$24 billion per year [4].  In the financial year of 2004-05, the direct cost of all 
musculoskeletal disorders was reported to be about $4 billion, $1.2 billion (30%) of 
which was related to OA.  Indirect costs of OA were much higher, estimated to be 
more than $7 billion in 2007.   
It is predicted that the demand for joint arthroplasty will increase substantially.  
In Australia, there were 67% and 40% increases in the number of arthritis-related 
knee or hip replacement surgeries, respectively, in a 7-year period from 2000-01 to 
2007-08 [120].  It is estimated that by 2030, the need for primary total hip (THA)or 
total knee (TKA) arthroplasty will  grow considerably in the Netherland and the US 
[139, 140].  This increase has been anticipated to be 174% and 673% for primary 
THR and TKA, respectively, in the US from 2005 to 2030 [139].  The growing trend 
is markedly due to the higher prevalence of some major risk factors, including an 
ageing population, obesity, and trauma to the joint.  People also wish to live quality 
lives, and improved techniques of anaesthesia and surgery have positively influenced 
their preference for surgery [119]. 
Medications used for chronic health problems like OA impose a fundamental 
financial cost especially on low income communities [141].  A survey was performed 
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in 2008 to find out how patients suffering from chronic conditions coped with their 
medication costs  [142].  In Australia, 1 out of 5 affected individuals (20%) reported 
that they ignored or underused their prescribed dosage due to the price.  The same 
strategy was also opted by some patients in the rest of the participating countries in 
the study, with the highest in the US (43%), 18% in Canada and New Zealand, and 
12% in Germany and France [142].  In another study, 5-22% of patients reduced 
their basic living expenditure, for example, their meals, in order to compensate for 
the OA management costs [143].  Either of these strategies can potentially have 
adverse effects on patients’ health and well-being and, can, consequently, further 
increase costs.  
 The pain or body stiffness presenting in OA can affect patients' daily life,   
limiting a wide range of activities: mobility, including household chores, self-care, 
access to health care providers, and many more.  OA can have an indirect impact on 
patients’ social activities and general health as well, leading to further reduction in 
their life quality [133].  Patients may have to change or even give up their job, or 
work limited hours.  These, in turn, could have an impact on their income, or result 
in depression and other emotional problems, as well as incur a substantial financial 
burden for governments and insurance companies [134].  In developed countries, 
musculoskeletal diseases were reported to be the second most common medical 
reason for short-term (< 2 weeks), and the most prevalent for long-term (>2 weeks) 
sick leave [144].  In fact, developing OA can potentially raise the risk of poverty due 
to either lower income because of leaving work or decreasing working hours, or 
having more expenses because of cost of the disease management and treatment 
[145].     
Further, physical limitations and psychological impact of OA can be 
exacerbated by environmental or individual hurdles.  Lack of access to public 
transport is an example of the environmental  barriers that can potentially contribute 
to the debilitation and lead to patients’ social isolation, limited access to health 
centres, nutrition deficiency, or increased dependency on others [146].  Patients' 
concerns about their joint deformity or their attitude towards dependency and 
disability can be considered as personal factors [134].  All of these situations can 
indirectly impose an extra burden on patients and the public.   
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1.4 CARTILAGE REPAIR STRATEGIES 
 
Given that cartilage is very susceptible to damage from injury or disease and 
has limited self-repair capacity, surgical interventions are usually needed to repair 
the lesion.  The treatment strategies can be divided into the two categories of 
conservative approaches and surgical interventions. 
  
1.4.1 Conservative approaches  
 
Various conservative approaches are available to relieve pain, reduce 
inflammation, and improve joint function in OA patients.  They play a role in OA 
management rather than treatment, and can relieve pain and improve function in the 
short- to medium-term [147] rather than cure the disease.   
 
Medications 
 
There is a wide range of old or novel medications that are commonly used to 
manage the disease.  Analgesics, particularly oral, non-steroidal anti-inflammatory 
drugs (NSAIDs) are the most widespread drugs for controlling the pain and 
inflammation associated with OA.  Apart from their benefits, they can have 
unwanted side effects among which gastro-intestinal irritations are recognized and 
common [148], and can vary from simple to serious problems.  Other organs might 
also be adversely affected; according to a recent study, the chronic use of NSAIDs 
increased the risk of heart disease [149, 150]. 
Glucocorticoids might also be injected into the affected joint, due to their anti-
inflammatory effects.  Despite having beneficial effects, however, their prolonged 
usage might have serious adverse effects which could, in turn, facilitate cartilage 
degeneration [151]. 
Injection or oral application of specific organic substances, which form the 
main structure of joint and articular cartilage, have become very popular in recent 
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years.  However, the mechanisms by which they attenuate OA symptoms are not 
fully known.   
Hyaluronic acid (HA) is injected into the joint as a successor for synovial fluid 
to lubricate articular surfaces, reduce friction, and subsequently, enhance the joint’s 
movement [148].  When it is injected intra-articularly, HA has a short half-life (up to 
24 hours), but its pain relief and anti-inflammation effects last for much longer [152].  
Detection of glutamate in the synovial fluid has been suggested to play an important 
role in progression of OA.  It has been reported recently that HA decreases the 
concentration of glutamate in synovial fluid of the injured knee joints and, therefore, 
slowdowns the cartilage demolition [153].  In another study, after intra-articular 
injection of HA, degradation of collagen type 2 was reduced [154].  
Chondroitin sulphate (CS) is another substance abundant in articular cartilage, 
which has beneficial effects in alleviating OA symptoms.  Reportedly, oral 
consumption of pharmaceutical-grade CS enhances proteoglycan and collagen type 2 
syntheses, decreases some pro-inflammatory and proteolytic factors’ production, and 
regulates chondrocytes’ metabolic activity [155].  However, more evidence from 
long-term studies is required to demonstrate the beneficial effects of this drug. 
Generally, the above-mentioned medications, as well as other novel drugs, 
have benefits in the management but not treatment of OA.  They appear to be 
beneficial in interrupting the progression of OA provided that they are applied in the 
early stages of cartilage defect.  Further research is needed on the mechanisms of 
action of these agents, their potential side effects, and their probable therapeutic 
benefits in OA patients.   
 
Other approaches 
 
There are also other methods that asset in the management of OA symptoms.  
Physiotherapy and specific exercises can have good outcomes in a joint’s movement 
and flexibility, especially when it is performed under the supervision of a skilled 
therapist or trainer [156].  A controlled diet should also be considered for losing 
weight and, consequently, reducing the load on the joint in over-weight or obese 
 38                                                                                                                                     Chapter 1: Literature review 
individuals.  The patient’s compliance and co-operation, however, are very important 
in achieving good results. 
 
1.4.2   Surgical treatments 
 
Various surgical techniques have been developed and performed to repair 
cartilage damages.  The primary objective of these strategies is to fill the void within 
the tissue that has resulted from the defect with a hyaline-cartilage-like tissue, and to 
achieve integration between the pre-existing and de novo cartilage [157].  This initial 
aim should lead to the ultimate goal, which is a pain-free and functional joint and 
patient satisfaction.  Despite remarkable improvements, none of the current 
techniques can lead to a repaired tissue that has bio-mechanical properties similar to 
natural articular cartilage.  Since the invention of arthroscopy, many of these 
procedures are performed arthroscopically, rather than through open surgery [158].  
Treatment through arthroscopy has resulted in less morbidity and quicker recovery, 
but there are still some disadvantages with current methods that limit their 
application. 
 
Debridement and lavage 
 
Localized cartilage defects that have affected up to half of the cartilage depth 
from its surface can be good candidates for debridement [159].  Removal of damaged 
cartilage (debridement) followed by joint irrigation (lavage), which are both 
performed through arthroscopy, may provide pain alleviation, and therefore, may 
have a positive therapeutic effect on osteoarthritis in its early phases of incident [160, 
161].  However, the symptoms of the disease are likely to return gradually as the 
damaged chondrocytes at the interface of normal and injured cartilage tissue are lost 
[162].  
 
 Effects of cartilage dust on cartilage formation in in vitro and in ectopic in vivo mode 39 
Marrow stimulating techniques 
   
Inspired by the natural body’s response to full-thickness cartilage lesions, bone 
marrow stimulation techniques are based on the stimulation of the normal healing 
process penetrating into the sub-chondral bone.  The original method was introduced 
by Pridie with aggressive removal of damaged cartilage and the subchondral bone to 
intentionally cause bleeding at the base of the defect [163].  Gradually, less 
aggressive procedures evolved from Pridie’s method, all of which benefited from the 
marrow stimulation concept, while conserving as much subchondral bone as 
possible.  Instead of completely removing the bone, in these modified techniques 
bleeding is provoked through gently abrading the bone surface by a burr, termed 
abrasion arthroplasty, or through creating small holes in the sub-chondral bone, 
termed microfracture [12, 164].  Subsequently, bone marrow-derived mesenchymal 
stem cells (MSCs), as well as signalling molecules such as TGF-β, make their way 
into the defect and are retained in a fibrin blood clot.  These cells differentiate into 
chondrocytes, but secrete mostly collagen type I, and subsequently, a fibrous 
cartilage is formed, although some areas of hyaline-like tissue consisting of collagen 
types II, VI, and IX may also be produced  [11, 12].  The newly formed fibrous 
cartilage is thinner than the native hyaline cartilage and is not strongly bonded to 
subchondral bone.  Therefore, the shear stress between the new and native tissue 
results in tissue degradation with the possibility of ossification [12, 40].  As a result, 
the joint function might not be fully recovered which, in turn, relatively limits the 
patient’s level of activity [107].  Indeed, despite satisfactory outcomes reported in the 
short- to medium-term, the joint’s function usually fails in the long-term and, 
therefore, the procedure is recommended for small, but not large cartilage defects 
[165].  The long term prognosis in the joints that have undergone this procedure is 
usually variable, partly because of the differences that arise due to the patients’ age, 
degree of activity, entity of the response, and dimensions of the defect [9].  It should 
be noted that there are two types of marrow in the body: red and yellow marrow, 
mainly consisting of haematopoietic and fat cells, respectively.  With ageing, red 
marrow gradually transforms into yellow marrow, with less concentration of 
pluripotent cells.  This physiologic change from red- into yellow-dominated bone 
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marrow may also happen in the sub-chondral bone, which could play a role in these 
procedures being less effective in ageing patients [166].   
 Since microfracture is a relatively simple and cost-effective method, with 
acceptable clinical outcomes in small- to medium-sized lesions, it has become the 
most performed procedure worldwide for cartilage repair [167].  However, the 
maximum size of the defect and the best age range of candidates to achieve optimal 
treatment results are controversial.  It has been reported that superior outcomes are 
expected for the defects smaller than 3 cm2, particularly in male patients, in single 
defects, and in the first performance [168].  
 
Periosteum and/or perichondrium transplant 
 
In this technique, periosteum or perichondrium, which are usually taken from 
tibia or the cartilaginous part of a lower rib, respectively, are transferred into 
osteochondral flaws [169, 170].  The graft contains healthy cells which are supported 
by a natural matrix, and protects the joint surface from being attached to its opposing 
joint surface before the repair process is completed [40].  As the procedure is done 
through open surgery, donor site morbidity is one of its major adverse effects. 
 
Osteochondral transfer 
 
Osteochondral transfer has been utilized mainly for the treatment of small to 
medium full thickness lesions.  In this reconstructive procedure, osteochondral plugs 
are taken from a non-load bearing site to repair a critical load bearing site [171].   
Autologous osteochondral transfer (mosaicplasty)  
 
 
In this method, which is also known as osteochondral auto-graft transfer 
(OAT), the donor and recipient are the same, and the procedure is performed in a 
single stage.  Since the transplantation is performed immediately after harvesting the 
graft, the graft is viable, and has a higher chance of survival compared to stored 
 Effects of cartilage dust on cartilage formation in in vitro and in ectopic in vivo mode 41 
allogeneic plugs.  However, applying one single plug, particularly in large defects, 
has limitations: enough donor tissue might be unavailable to fully cover the defect; 
giver site morbidity is inescapable; and the management of the procedure is difficult 
[167].  
To address some of the OAT limitations, mosaicplasty was introduced which is 
a modified version of OAT in which multiple but smaller plugs are taken from the 
donor site [172].  Hangody et al. improved mosaicplasty in the early 1990s, when the 
procedure was performed through arthroscopy [171], and reported promising clinical 
outcomes after a long-term follow up (approximately 15 years), especially in treating 
small cartilage lesions [173].  In spite of satisfactory clinical results, limited 
availability of graft tissue, poor integration with the surrounding cartilage, and 
donor-site morbidity remains unsolved [174].  In fact, increasing the patient’s age or 
the dimensions of the defect has been found to have an adverse effect on clinical 
outcomes [175].  In a long-term study, inferior results were reported in patients older 
than 40, in lesions greater than 3 cm2, and in females compared to men [176].  The 
method can be performed through either arthroscopy or open surgery, and there 
appears that there is no significant superiority between them in terms of precision 
and accuracy [177].  
 
Allogeneic osteochondral transfer 
 
In this method, the osteochondral block is taken from another person, stored in 
specific conditions, and transplanted into the recipient site.  Alternatively, fresh 
grafts could be used, as the biological and biomechanical properties of the graft are 
lost over time and are due to cryopreservation [178].  Compared to autologous grafts, 
possessing a greater supply of donor tissue, as well as lacking donor site discomfort, 
have been considered the merits of applying allograft [179].  Allogeneic osteo-
chondral transplants are generally considered to be immunoprivileged, but antibodies 
have been detected in some patients that are consistent with their less desired clinical 
results, compared to their antibody-negative counterparts [180].  Therefore, 
immunological rejection of the graft is probable, and the possibility of disease 
transmission is also of concern with this method  [147]. 
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Joint arthroplasty 
 
Despite the potential alleviation of pain and the functional improvement 
resulting from the methods mentioned above, the resulting repaired tissue is 
generally dissimilar to the natural joint structurally or biomechanically [13].  In most 
cases the degenerative process continues until replacement of part of the joint or its 
entirety becomes inevitable [147].  Indeed, arthroplasty is the last resort option when 
other more conservative or minimally-invasive treatments are no longer effective 
[148].  In this procedure, the bony part of the joint is reconstructed from artificial 
pieces.   
In general, joint arthroplasty has been shown to have a satisfactory clinical 
outcome, particularly in patients older than 55 years [148].  However, there is the 
possibility of adverse effects after performing this procedure, which could be either 
local, or systemic.  Local unwanted results are those limited to the prosthesis, such as 
infection, stiffness, and loosening, among which infection is the most common, and 
can potentially lead to a secondary operation.  Systemic complications are highly 
uncommon, but can be potentially life-threatening and fatal.  Wound infection, 
pneumonia, myocardial infarction, and even death are examples of systemic failure 
of total joint arthroplasty, especially regarding the knee joint [148, 181].  
Taken together, current reparative or restorative techniques for cartilage repair 
still need to be improved to fulfil the ultimate goal of the treatment, which is the 
regaining of the joint’s function and complying with patients' expectations.   
 
Autologous chondrocyte implantation (ACI) 
 
Autologous chondrocyte implantation (ACI) is a cell-based method for the 
treatment of articular cartilage defects in which chondrocytes are obtained from a 
less weight-bearing area through arthroscopy, and are utilized to repair a more 
essential load bearing defect area.  Isolated cells are separated from the ECM by an 
enzymatic digestion and then expanded in culture for about 6 weeks.  Subsequently, 
after debriding the chondral lesion and preparing a periosteal flap through a process 
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termed arthrotomy, the chondrocytes are transferred into the region and covered with 
a periosteal flap [182].  Alternatively, a collagen membrane may be applied instead 
of a periosteal flap to preserve the chondrocyte phenotype, as well as prevent 
fibroblast infiltration into the graft [183].     
Generally, ACI is indicated in younger adults suffering from chronic joint 
symptoms related to a localized full-thickness lesion, usually in the knee [184].  
There are a number of limitations associated with the ACI procedure.  First there is 
the necessity for preliminary surgery and tissue biopsy to recover the chondrocytes, 
which may result in donor site morbidity on an already defective joint [185].  
Second, the process of expanding the chondrocytes ex vivo often results in 
dedifferentiation, with the cells producing collagen types I, III and V, instead of 
collagen types II, IX, XI and aggrecan [186]. As a result, the cell specific properties 
that made the chondrocyte a logical starting cellular material are lost and the tissue 
formed may be fibrous rather than hyaline cartilage [174].  Third, the chondrocyte 
expansion process requires the use of foetal bovine serum as a source of growth 
factors to maintain cartilage specific SOX9 expression.  The use of this serum carries 
a risk of pathogen transfer, as well as the potential to provoke an immune response in 
the patient.  In addition to these concerns, there is debate regarding the actual 
mechanism by which this process may enable cartilage repair.  It could be argued 
that repair is mediated by progenitor cells residing in periosteal graft or bone marrow 
rather than the cultured chondrocyte population.  This argument could be partially 
muted by the successful use of the collagen membrane in place of the periosteal graft 
[187]. 
It is predicted that through tissue engineering it will be possible to develop 
superior methods to repair damaged tissues, with the goal of mimicking native tissue 
both functionally and morphologically [9].  
 
 
 
1.5 TISSUE ENGINEERING AND REGENERATIVE MEDICINE 
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Generally, tissue engineering was first described as the ex vivo implantation of 
specific cells, either stem cells or cells isolated from any given organ, in a scaffold.  
What distinguishes the tissue engineering from “guided tissue regeneration” is that in 
the latter a scaffold is transplanted to the related site to instruct resident cells to repair 
the tissue [188].  Following recent advancements, the definition of tissue engineering 
has been expanded to also include in vivo remodelling of a scaffold, whether seeded 
or not seeded with cells, and it is termed tissue regeneration or tissue reconstruction 
[189]. The major components of a tissue-engineered construct are appropriate cells, a 
suitable scaffold, and an optimal microenvironment, including signalling molecules, 
biomechanical stimuli and chemical factors [190].   
Figure 1.2 shows two potential tissue engineering strategies for cartilage repair.  
Cells may either be prepared in vitro and then injected into the defect, allowing the 
rest of the process to take place in the tissue (cell-based or in vivo tissue 
engineering), or alternatively, they can be used to build an engineered construct 
which has full function in vitro before being transferred to the body (scaffold-based 
or ex vivo tissue engineering) [17]. 
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Figure 1.2. Schematic diagram of the cartilage tissue engineering process.  
There are two basic approaches to cartilage tissue engineering. In ex vivo tissue 
engineering, the tissue is generated entirely in vitro with full functionality before 
being transplanted, while in in vivo tissue engineering, the construct is implanted 
with or without prior partial in vitro cultivation, and allowed to mature in vivo for 
repair and regeneration. Both approaches require appropriate scaffolds, responsive 
cells, and a chondroinductive and chondro-conductive environments [17]. 
Image reprinted here by permission from the Nature Publishing Group (see Appendix 
B). 
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1.5.1 Cell sources 
 
Cells usually used in articular cartilage tissue engineering are either 
chondrocytes harvested from mature cartilage or MSCs harvested from bone marrow.   
 
Articular Chondrocytes 
 
Articular chondrocytes appear to be the preferred cells as they originate from the 
native tissue, and possess optimal potential and proper phenotype for cartilage 
regeneration.  Isolated cells are separated from the ECM by an enzymatic digestion 
and then expanded in culture.  Interestingly, the use of chondrocytes from different 
zones of hyaline cartilage may influence the characteristics of the de novo cartilage 
[191].  
 
 
Mesenchymal stem/stromal cells (MSCs) 
 
Despite the popularity of using chondrocytes for cartilage tissue engineering, 
the possibility of dedifferentiation and the limited expansion potential of 
chondrocytes, as well as morbidity in donor sites, present significant obstacles for the 
application of chondrocytes and, as a result, there is increasing interest in the 
employment of MSCs instead of chondrocytes for such procedures [192].  They are 
rapidly becoming the preferred cells for both cell-based and scaffold-based tissue 
engineering as they can be relatively easily harvested in large numbers, are easy to 
expand in vitro to provide therapeutic cell quantities, and are capable of undergoing 
chondrogenic differentiation following in vitro expansion [193].  Furthermore, for 
the successful treatment of inflammatory and immune diseases, such as OA or 
rheumatoid arthritis (RA), MSCs may be a good cell source due to their anti-
inflammatory and anti-immunogenic potential [18, 194]. 
Various tissues other than bone marrow, such as adipose tissue, muscle, 
synovium, and dental pulp can be a source of MSCs [195].  Sakaguchi et al. 
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compared the chondrogenesis ability of human MSCs derived from different origins, 
including bone marrow, synovium, periosteum, skeletal muscle and adipose tissue 
and demonstrated that the highest chondrogenic potential belonged to MSCs derived 
from synovium, bone marrow and periosteum, respectively [196].  However, bone 
marrow-derived MSCs are thought to be preferred for cartilage repair applications 
due to their capacity to differentiate into cartilage, their quantitative availability, the 
minimally invasive methods available for obtaining them, and the belief that they 
preserve their differentiation potential while proliferating [197].  More research is 
needed to conclusively establish the best tissue of origin for MSCs for a particular 
application [17].  
In addition to tissue origin, factors such as a patient’s age and disease phase 
may have an influence on the potential and speed of MSC replication [17, 18].  
According to Murphy et al., MSCs in patients with advanced OA, compared with 
those in healthy donors, have minimal proliferation and chondrogenic differentiation 
capacities, and show a tendency toward osteogenicity [198].  However, adding 
specified amounts of parathyroid hormone-related peptide (PTHrP) to the culture 
suppresses the expression of collagen type X (indicators of osteogenesis) and also 
lowers the activity of alkaline phosphatase, resulting in the maintenance of cartilage 
matrix properties [199]. 
 
 
1.5.2   Scaffolds 
 
Scaffolds are required to prepare an interim structural support, along with 
biological signals to guide cells to produce a specific ECM.  Mechanical features, 
architecture, and chemical composition of the matrix surrounding the cells can have 
an important impact on cells’ behaviour [200].  An appropriate scaffold for tissue 
engineering should have biocompatibility properties so as to not provoke 
immunogenic reactions, as well as have appropriate biodegradability and 
bioresorbability properties that are proportionate to the formation rate of newly 
produced ECM, sufficient pores, permeability, and suitable biomechanical properties 
[190].  Characteristics of the tissue to be regenerated, for instance, its density, 
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biomechanical features, and biochemical composition, are very important in 
designing the tissue’s scaffold.  Each specific tissue has its own unique composition 
and ultrastructure that is perfectly designed for its function which, if simulated, can 
improve the ultimate biological role of the given scaffold [201].  Optimal interaction 
with cells must also be considered in scaffold design, since it has a profound effect in 
cell phenotype.  This communication can change the state of the cell, and cause 
modification in cell surface receptors and ligands [201].   
Scaffold materials used for articular cartilage tissue engineering can be 
generally subdivided into three categories: natural (carbohydrate-base and protein-
based); synthetic; and hybrid [9].  Collagen and fibrin are examples of natural 
protein-based scaffolds, while alginate, chitosan and hyaluronan are examples of 
natural carbohydrate-base scaffolds [174].  Decellularized organs and tissues, which 
are also known as natural or biological scaffolds, have held huge promise in the 
tissue regeneration field.  This issue will be discussed later in this chapter (section 
1.6) in a separate subtitle due to its relevance to this thesis.  
In osteochondral defects both cartilage and underlying bone are damaged.  To 
replicate this normally, hybrid scaffolds that have well-integrated load-bearing 
structures, with different layers to replicate this complex structure could lead to 
better treatment outcomes [202].  Further, hybrid scaffolds may help the reproduction 
of the zonal variety of hyaline cartilage present in vivo [99].  
 
 
1.5.3   Environment and microenvironment 
 
Each tissue has a specific microenvironment which may vary in its different 
parts.  Indeed, being able to control the microenvironment in vitro, or to simulate the 
tissue-specific niche that is found in vivo is pivotal in tissue engineering [189].  
Oxygen concentration, pH, nutrient availability, and mechanical stimuli are some 
microenvironmental examples. 
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Bioactive Factors 
 
Signalling molecules, that are growth factors, hormones and cytokines, have a 
significant impact on mesenchymal stem cells and chondrocytes.  Therefore, it is 
necessary to use these in tissue engineering, along with cells and scaffolds [174].  
It has been shown that fibroblast growth factor-2 (FGF-2) has the most 
important role in driving the proliferation of MSCs, as well as preserving their 
capacity to differentiate.  This factor allows the cells to be expanded in the culture, 
after which they can be differentiated into specific mesenchymal lineages via 
stimulation with appropriate agents, hence producing relevant tissue [43, 203].  
Transforming growth factor β (TGF-β) regulates the production of fibronectin 
in the initial stage of condensation.  Fibronectin, in turn, controls N-CAM (a 
molecule that facilitates adhesion of cells) in initiation and the proliferation stages of 
chondrogenesis [45].  More specifically, N-cadherin and N-CAM regulate contact 
between cells. N-cadherin starts the compaction of cells in culture, which is then 
maintained by N-CAM [43].  To stop condensation and start differentiation, factors 
regulating the compaction of cells, such as N-CAM need to be downregulated.  In 
contrast, factors associated with differentiation, such as bone morphogenic protein 
(BMP) need to be upregulated [45]. 
Bone morphogenic protein (BMP), which belongs to the transforming growth 
factor β (TGF β) family, regulates the pathways of parathyroid hormone-related 
peptide/Indian hedgehog (PTHrP/Ihh) and fibroblast growth factor (FGF) [204, 205]. 
Ihh and PTHrP have an important role in the hypertrophy of chondrocytes [44].  
Terminally differentiated chondrocytes produce collagen type X both in vivo and in 
vitro, which is associated with the appearance of alkaline phosphatase, the prevention 
of cell growth and cell death. PTH/PTHrP suppresses this process, and helps these 
cells to proliferate.  In other words, the role of PTHrP is to switch and preserve 
differentiated chondrocytes in a pre-hypertrophic and pre-osteoblastic state, thereby 
prohibiting cell death and ossification [43].  
According to Gouttenoirre et al., TGF- β1 and BMP-2 have roles in regulating 
collagen type IIA and collagen type IIB expression in murine chondrocytes, 
respectively.  Therefore, dedifferentiation of chondrocytes could be switched by 
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BMP-2 [206].  When injected locally into the knee joint of mice, both of these 
growth factors stimulated production of desirable proteoglycans.  TGF- β was more 
effective than BMP in stimulating this production, however, both had the ability to 
induce less desirable osteogenesis and fibrogenesis [207, 208]. 
 
Bioreactors 
 
Bioreactors are used to establish suitable environments for the proliferation and 
differentiation of MSCs in vitro [17].  They enable the replication of native tissue 
biochemistry and mechanical loading [209].  The standard culture conditions 
generally employed are 37oC temperature, 90-100% humidity, 20% O2, and 5% CO2 
[3].  However bioreactors are well suited to enable further tailoring of these 
physiochemical parameters.   
It has been shown that 50-60% of the glycosaminoglycans secreted by bone 
marrow-derived MSCs during chondrogenic differentiation are lost to the bulk 
culture medium, making this loss one of the significant limitations in ex vivo 
cartilage production [210].  Doran et al. showed that bioreactor systems with a 
membrane that has a molecular weight cut-off less than collagen II or aggrecan could 
be used to prevent the loss of critical matrix molecules, as well as to minimize the 
use of costly growth factors, thereby improving the properties of the tissue 
engineered cartilage [210]. 
 
High-Density culture systems 
 
Traditionally in these protocols, a large numbers of MSCs are condensed into a 
single pellet by centrifugation.  This crudely mimics the natural condensation process 
that occurs in foetal hyaline cartilage development.  The number of cells generally 
used in these assays are 2-2.5 x 105, with up to 5 x 105 cells per pellet [20]. 
 Three-dimensional, high-density cell culture systems have been routinely 
utilized for the in vitro study of MSC chondrogenic differentiation [16, 17] as well as 
for investigating the role of factors that steer this process [19].  Scaffolds are not 
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employed in these systems and chondrocytes or MSCs synthesize the whole tissue, 
therefore, the regenerated cartilage tissue has more similarity to native tissue than if 
it contained a synthetic scaffold [211].  However, the secreted ECM is not uniformly 
produced throughout the pellet and thus the resulting tissue is extremely variable.  
This variability is most likely a result of the significant diffusion lengths and 
resulting inadequate nutrient supply that exist in these rather large macropellets [16]. 
 
Mechanical forces 
 
Chondrocytes residing in articular joints are adapted to a wide range of 
mechanical forces, among which hydrostatic pressure (HP) is the most common 
dynamic force.  Many years ago it was known that various amounts of HP applied to 
articular cartilage explants can be transformed by chondrocytes into metabolic 
events, in a magnitude-dependant manner [212].  In a study by Correia et al., the 
development of cartilage tissue by either chondrocytes or adipose-derived stem cells 
was assessed in a custom-made bioreactor, applying various ranges of physiologic 
mechanical loading, in terms of amplitude and frequency, and compared with a static 
culture condition.  Application of pulsative HP resulted in the foremost tissue 
development in both chondrocyte and adipose-derived stem cell groups compared to 
static cultures [213].  
 
Oxygen tension 
 
The oxygen gradient that exists in large pellet cultures may be an essential 
factor in driving the in vitro chondrogenesis process.  Hypoxia-inducible factor (HIF-
I) has a key role in sensing the hypoxia experienced by cells [214].  Low oxygen 
environments activate the HIF-1α residing in the cytoplasmic matrix and then this 
factor is translocated to the nucleus where, with the aid of HIF-1β, it initiates the 
transcription of genes related to hypoxia, such as erythropoietin.  HIF-1 also up 
regulates SOX9 (chondrogenic transcription factor) that is followed by collagen II 
and aggrecan directing the chondrogenic phenotype in vivo [214]. 
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Krinner et al. (2009) observed that ovine bone marrow-derived MSCs 
expanded under 5% oxygen tension demonstrated higher proliferation rates and 
resulted in larger colonies compared with their counterparts cultured under 20% 
oxygen tension. However, this hypoxic environment appeared to block some MSC 
differentiation pathways in favour of the maintenance of the MSC phenotype [215].  
It has also been shown that the chondrogenic and osteogenic capacities of murine 
adipose-derived mesenchymal cells (AMCs) in long-term culture conditions of 2% 
oxygen is considerably limited compared to AMCs grown in 20% oxygen tension 
conditions [216].  Because MSCs undergo chondrogenic differentiation in a hypoxic 
atmosphere, AMCs may be not suitable for cell-based cartilage repair strategies. 
 
 
1.6 APPLICATION OF DECELLULARIZED TISSUES AND ORGANS IN 
REGENERATIVE MEDICINE 
 
ECM-derived scaffolds have resulted in considerable advancements in tissue 
regeneration and repair.  These biological scaffolds owe most of their advantages to 
the composition, structure, and organization of the tissues of origin, which could be 
largely saved after being processed.  The resultant decellularized bioscaffolds can be 
used as guides for the cells to repopulate the scaffolds, and ultimately regenerate and 
repair the tissue.   
Biodegradability in vivo, without producing any toxic by-products, plays an 
important role in this regard.  While degrading, these scaffolds release biologically 
active molecules that can be used by the host cells as biological cues to induce the 
“constructive remodelling” [26, 189, 217, 218].  Indeed, the age of donor, how 
efficient the naturally occurring ECM was decellularized, and whether the 
bioscaffold was chemically crosslinked affect in vivo remodelling of the bioscaffold 
[219].  Whether the composition or the structure of the original ECM has the most 
importance in the reconstruction is a matter of controversy [24]. 
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1.6.1 Bioinductive activities of ECM-derived scaffold materials 
 
The bioinductive characteristics of biological scaffolds have pivotal effects on 
the “constructive remodelling” of host tissue, however, a little is understood 
regarding the mechanism [26].  Biological scaffold materials can stimulate 
angiogenesis, as well as mitogenesis, migration, and differentiation of cells in the 
host tissue [217].  While degrading, the biological scaffold releases factors which 
attract the recipient’s stem and progenitor cells to the related location where they can 
differentiate into tissue-specific cells and secrete new ECM [220].  Further, their 
degradation products can have remarkable biological effects, for example, 
antibacterial activity, due to the release of their bioactive molecules [221].  The 
biological activity of ECM-derived materials is related to degradation of their sound 
3D ultrastructure, in contrast to their biomechanical and structural features, which are 
related to a sound 3D structure.  Appreciating the degradation rate and composition 
as well as the essence and distribution of degradation products are important in the 
precise estimation of the biological practicality of a given biological scaffold in vivo 
[217]. 
 
1.6.2 Biomechanical properties of ECM-derived scaffold materials 
 
Biomechanical characteristics of a decellularized tissue is highly dependent on 
the organization of its collagen fibres, and can change under loading [24].  Like 
bioinductive properties, biomechanical characteristics of a biological scaffold can be 
highly affected by the processing methods and stages.  Clearly, different forms of 
biological scaffolds, for example, gels compared to sheets, are not expected to have 
similar mechanical properties [26].   
Appropriate mechanical characteristics or the morphology of the bioscaffold to 
the recipient tissue are important parameters at the time of implantation, however, 
the host immune reaction and its subsequent effect on form and function of the 
bioscaffold are determinant factors in the success or failure of the treatment [219]. 
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1.6.3   Immunogenicity of ECM-derived scaffold materials 
 
The host’s immune system responds to all biomaterials, even those known as 
inert, and it is the type of this reaction that results in different outcomes [222].  
Whether a biological scaffold material could potentially provoke an adverse immune 
reaction in the host would be more considerable in the application of xenogeneic 
biological scaffolds, although bioscaffolds originating from non-autologous tissues 
have been applied successfully for many years [26].  For example, small quantities of 
galactosyl 1, 3 galactose epitope (gal-epitope) can be present in porcine small 
intestine-derived (SIS-derived) scaffolds without being rejected by the host immune 
system after implantation [223].  Since most of the studies regarding the 
immunogenicity of bioscaffolds have been done on materials derived from porcine 
SIS [217], more research is required to evaluate the possible immunogenicity of 
other xenogeneic ECM derived materials.  
Manufacturing processes which slow down the degradation rate of 
bioscaffolds, for example, cross-linking, also could cause foreign body reaction in 
the host rather than constructive tissue remodelling [219]. 
 
1.6.4   Processing methods and their effects on structure and function of   
biological scaffold materials 
 
To be suitable as a biological scaffold material, the original tissue must 
undergo multiple processing steps, which can significantly alter the structure, as well 
as the host immune response [24].  Figure 1.3 illustrates various steps and processing 
procedures, which will also be discussed in the following section. 
 
Decellularization 
 
When applying allogeneic or xenogeneic ECM-derived materials, their cellular 
antigens should be effectively reduced such that the adverse immune response is 
attenuated, as these antigenic epitopes are recognized as foreign bodies by the host 
immune system [24].  Decellularization is basically done chemically, enzymatically, 
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or physically, all of which result in some degree of change in either the composition 
or ultrastructure of the source tissue.  It has been recommended that cellularity, 
density, thickness, and fat content of the tissue of origin should be considered, when 
choosing an agent or method for decellularization [224]. 
 
 
 
 
Figure 1.3. Layout of processing steps for various forms of extracellular matrix 
scaffolds.  
The hydrated sheet can be used as a scaffold material directly. Several hydrated 
sheets can be vacuum pressed to make a multilaminate scaffold device. The hydrated 
sheets can also be lyophilized sheets. The lyophilized sheets can be comminuted to 
make a particulate form of the material. The comminuted material provides can be 
enzymatically digested to make a liquid form of the material, which can be re-
polymerized into a gel or mixed with a synthetic polymer to make a hybrid scaffold. 
Image taken from [217], see appendix for permission. 
Image reprinted here by permission of Copyright Clearance Centre (Appendix C). 
 
 
Deleting cellular antigens while protecting the original features of the source 
tissue as much as possible is the ultimate objective of any decellularization 
technique.  However, current methods are not sufficient to produce a completely cell-
free scaffold, and some DNA remains in the final scaffold material [225].  
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Dehydration 
 
Dehydrated tissues are normally handled more easily than the hydrated ones, 
and the loss of biological factors during their storage time is also minimized [24].  
Commonly used techniques for tissue dehydration include lyophilisation and vacuum 
pressing.  
 
Lyophilisation (freeze drying) 
 
In this method low temperature and low pressure causes water to be sublimed 
from the tissue [24].  Although the process increases the storage time of the 
processed material while retaining most of the tissue strength, it also possesses some 
disadvantages.  Morphology of collagen fibres and proliferation of the seeded cells in 
vitro might change due to the freeze drying process [226].  Further, the thickness of 
the source tissue is reduced by almost 30% following lyophilisation, which results in 
more compacted fibres in the scaffold.  Tissue GAG is also disrupted, which causes 
the material, when rehydrated, to reabsorb a lesser amount of water compared to the 
original tissue [227, 228].     
 
Vacuum pressing 
 
This technique is applied when several layers of ECM are required to improve 
the scaffold’s strength and mechanical features, and is beneficial for manufacturing 
different shapes of scaffold materials [24].  Through this method the construct 
becomes less extensible, and morphology of the native tissue alters [226].  
 
Hydration 
 
In this method water is not lost from the ECM while the source tissue is being 
processed.  As a result, minimum changes occur in the tissue morphology, and 
seeded cells can attach to the scaffold and penetrate through it better compared to the 
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dehydrated materials [226].  However, the main drawback of the method is that 
soluble biological factors are continuously lost from the hydrated constructs during 
its storage [24]. 
 
Powdered ECM scaffolds 
 
Lyophilised ECM can be processed further to form particles with various sizes.  
The ultrastructure and 3D superficial features of the original lyophilised sheet is 
preserved in the resultant particles, however, it is not envisaged to have load-bearing 
capacities on their own  [24].  The particulate form of ECM can subsequently be 
applied in different ways.  It is applicable as a suspension, can be compacted to form 
various 3D- shapeed constructs, may become part of a hybrid scaffold, or can even 
be injected topically into the target sit [229]. 
 
ECM gel 
 
ECM may be processed to become soluble and form a gel after being used.  
This would make it more easily applicable compared to the suspension form, and 
could take the shape of a defect to which it has been applied, while retaining the 
biological factors of the tissue of origin [226].  However, the aggressive processing 
steps for the purification of the gel, which may be responsible for the loss of the 
native tissue’s biologically active molecules, could be improved [230].    
 
Sterilization 
 
The sterilization process, which is usually the final step in manufacturing 
ECM-derived scaffolds, can adversely affect some properties of the product.  For 
example, it was reported that gamma irradiation, depending on its dosage, reduced 
the mechanical properties of a dermis-derived scaffold [231]. 
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1.6.5 Hybrid scaffolds 
 
In addition to original properties of a native tissue from which the biological 
scaffold is being derived, such as mechanical features and even the age and health of 
the donor, the processing stages can also have a role in the final properties of the 
resultant scaffold material.  These features can be modified to achieve a scaffold 
meeting some requirements that are necessary for its application [24].  Increasing 
mechanical strength of the final scaffold by multilaminating the decellularized 
human amniotic membrane [232] is an examples in this regard.  Another way for 
manipulating features of an ECM-derived material is to combine the material with 
synthetic constructs to create a hybrid scaffold, for instance, incorporation of poly 
(D,L-lactide-co-glycolide) (PLGA) and SIS to create a PLGA-SIS hybrid scaffold for 
disc regeneration [233].  The hybridization, however, combines features of both 
materials.  Stated differently, the resultant scaffold possesses not only the 
advantages, but also the disadvantages of both materials [24]. 
One could predict the application of decellularized xenogeneic organs seeded 
with a patient’s own cells in the future, namely xenotransplantation.  These so called 
“hybrid organoids” would be able to address the shortage of human donors through 
using, for example, porcine organs, while at the same time not requiring 
immunosuppression after being transplanted because they are repopulated with 
autologous cells [234]. 
 
 
1.6.6   In vivo remodelling of bioscaffolds 
 
While remodelling in vivo, ECM-derived scaffolds can show different 
mechanical properties depending on various factors, for example, the host tissue’s 
micro and macro environments, and the rates of biodegradation of the scaffold and 
repopulation by resident cells [24].  It has been shown that the strength of scaffolds 
derived from SIS-ECM temporarily decreases in the earlier stages after in vivo 
implantation, since the scaffold’s degradation happens quicker than the maturation of 
the newly secreted ECM.  Later, when the deposited ECM becomes more mature and 
organized, it becomes stronger, even when compared to the strength of the native 
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tissue [235].  Mechanical loading applied at various stages of in vivo remodelling, 
however, can alter the outcome [236].   
 
1.6.7   Recellularization challenges 
 
Attachment, penetration, and homogenous repopulation of cells within an 
ECM-derived bioscaffold, as well as optimal cell density, phenotype, 
communication, distribution comparable to the source tissue, and optimization of 
culture condition and duration are among the main issues in achieving successful 
outcomes of recellularization [237].  Further, density, pore size, and shape of the 
decellularized tissue have pivotal roles in recellularization outcome.  Cell seeding 
onto a decellularized tissue can be improved using bioreactors [237]. 
 
1.6.8   Decellularized articular cartilage 
 
 
Decellularized cartilage has been used experimentally in various forms, such as 
tissue pieces [30], or tissue sheets [34].  In 1998, decellularized cartilage pieces were 
effectively bonded together by chondrocytes being cultured between the pieces.  The 
quality of the regenerated tissue continuously improved over the six-week period of 
in vivo implantation.  However, repopulation of the decellularized cartilage happened 
superficially rather than throughout the bioscaffold [30], since it was difficult for the 
chondrocytes to migrate through dense cartilage ECM.  Indeed, cartilage’s dense 
matrix is responsible for both its decellularization and subsequent repopulation 
difficulties [28].  Taking this into consideration, researchers have tried to minimize 
the thickness of cartilage ECM-derived scaffolds.  For instance, it was reported that 
penetration of seeded chondrocytes was enhanced when cartilage sheets with the 
thicknesses of 10-30 μm were used [34].  Therefore, it was reasoned that microscopic 
particles of allogeneic decellularized cartilage matrix, which hereafter are called 
cartilage dust (CD), could be mixed with chondrocytes, and ultimately integrated into 
the de novo tissue following in vivo implantation. 
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1.7 AIMS AND HYPOTHESIS 
 
The aim of this project was to achieve decellularized articular cartilage 
particles smaller than 10 µm, and to demonstrate that expanded chondrocytes could 
integrate well with these particles, and ultimately regenerate cartilage tissue in vivo.    
 We developed a new method for cartilage tissue decellularization and 
pulverization.  We termed this powdered, ECM-derived material cartilage dust (CD).  
CD can be combined with various methods of cartilage tissue engineering, using 
different types of cells, for example MSCs or chondrocytes.  Human articular 
cartilage cells and CD derived from human articular cartilage were used in this study. 
 
Hypothesis:  It was hypothesize that small particles of decellularized articular 
cartilage (CD) could be applied as an ECM derived scaffold material with articular 
chondrocytes, to regenerate a more mature tissue in vitro, and ultimately in vivo.   
 
Overall AIM:  The overall aim of this project was to optimise the formation of 
composite, cartilage-like tissues from chondrocytes and CD, and to characterise the 
CD integration within composite tissues matured in vitro and in vivo. 
 
       AIM 1:  Optimize production of cartilage tissue in vitro using expanded 
chondrocytes combined with particles of third party donor cartilage 
ECM (CD).   
AIM 2:  Evaluate the incorporation of particles of third party donor   
cartilage ECM (CD) into cartilage tissues formed from expanded 
chondrocytes.   
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1.8 THESIS STRUCTURE 
 
The results from this project are presented in Chapters 2 and 3.  Chapter 2 is a 
published paper which describes work related to AIM 1 (in vitro characterisation of 
CD incorporation into cartilage-like tissues).  Chapter 3 is unpublished work 
presented in manuscript form.  It describes results related to both AIMs 1 and 2.  
Individual chapters contain the relevant methods, results and discussion sections.  In 
Chapter 4 overall conclusions is outlined, and future directions are suggested. 
 
1.9 SIGNIFICANCE, SCOPE AND DEFINITIONS 
 
 
The incorporation of the powdered cartilage ECM, termed cartilage dust (CD), 
with cartilage cells is likely to result in a more mature cartilage tissue in vitro, and 
subsequently in vivo.  Not only is this likely to provide a superior model system for 
cartilage developmental biology, it could make a critical contribution to potential 
future cartilage repair strategies. This project is a logical first step towards the 
development of a novel cartilage generation process that can offer a viable solution 
for joint repair in osteoarthritis patients, and that such technology is likely to be 
critical for the clinical repair of large cartilage defects from patients’ own cells.  
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Chapter 2: The Rationale for Using 
Microscopic Units of Donor 
Matrix in Cartilage Defect 
Repair 
2.1 ABSTRACT 
 
The efficacy of existing articular cartilage defect repair strategies is limited.  
Native cartilage tissue forms through a series of exquisitely orchestrated 
morphogenic events spanning through gestation into early childhood.  However, 
defect repair must be achieved in a non-ideal microenvironment over an accelerated 
time frame compatible with an adult patient.  Scaffolds formed from decellularized 
tissues are commonly utilized to enable the rapid and accurate repair of tissues such 
as skin, bladder and heart valves.  The intact extracellular matrix remaining 
following the decellularization of these relatively low-matrix density tissues is able 
to accurately and rapidly guide host cell repopulation.  By contrast, the extraordinary 
density of cartilage matrix actually limits both the initial decellularization of donor 
material and its subsequent repopulation.  Repopulation of donor cartilage matrix is 
generally limited to the periphery, with repopulation of lacunae deeper within the 
matrix mass being very inefficient.  Herein, we review relevant literature and discuss 
the trend towards the use of decellularized donor cartilage matrix of microscopic 
dimensions.  We show that 2 µm microparticles of donor matrix rapidly integrate 
with articular chondrocytes, forming robust cartilage-like composites with enhanced 
chondrogenic gene expression.  Strategies for the clinical application of donor matrix 
microparticles in cartilage defect repair are discussed.   
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2.2 INTRODUCTION 
 
Scaffolds derived from decellularized tissues have enabled advancements in 
tissue engineering that, in many cases, exceed what has been possible using synthetic 
approaches.  Much of the value of these scaffolds is associated with the fact that the 
extracellular matrix (ECM) composition and organization remain largely intact 
following the decellularization process.  The remaining high-resolution chemical and 
physical architecture guides accurate repopulation of the decellularized donor tissue 
with host cells.  Successful tissue repair in the clinic, and even partial restoration of 
organ function in vitro, has motivated attempts to regenerate virtually all tissues of 
the body using these same strategies.  Cartilage is an ECM-rich tissue that, in theory, 
should be ideally suited for regeneration via the decellularization approach.  
However, this very feature makes classical decellularization and repopulation 
strategies non-viable.  Here we briefly review the literature in this area, and describe 
what we believe is an evolution towards the use of microscopic units of donor 
cartilage matrix in articular cartilage tissue engineering.   
 
2.3 THE USE OF EXTRACELLULAR MATRIX (ECM) IN TISSUE 
REPAIR 
 
ECM is a product secreted by the cells that populate a given tissue or organ 
[238].  The functions of ECM are many, and their precise role in specific tissues may 
vary somewhat.  However, in general, the ECM plays the role of nature’s ultimate 
scaffold providing structural support, facilitating cell-cell communication, 
functioning as a reservoir for the controlled release of growth factors, as well as 
being fully biocompatible and biodegradable.  The complex architecture of the ECM 
is designed and manufactured by the resident cell population, and in turn it can 
accurately facilitate its own repopulation by new cell populations, thereby playing a 
critical role in tissue regeneration.  This is a complex, and somewhat circular 
relationship that is initially driven through morphological processes staged during 
embryonic and fetal development.  Replication of these morphological events, or the 
resulting tissue ECM architecture, remains beyond existing scientific technologies.  
In fact, it is accurate to say that even the full composition and organization of tissue 
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specific ECM remains unknown.  For this reason, some of the most successful tissue 
engineering outcomes have so far utilized portions of decellularized tissues, rather 
than synthetic mimics.  The clinical application of this concept is rapidly becoming 
routine, with decellularized donor tissue being utilized in skin repair, heart valve 
replacement, bladder repair/replacement, hernia repair, as well as many other 
reconstructive procedures [239].  Experimentally, whole organ decellularization of a 
rat heart, followed by its semi-functional repopulation, has been reported [240].   
 
2.4 CARTILAGE IS AN ECM-RICH TISSUE 
 
The volume ratio of ECM in cartilage is in excess of 95%, making it a uniquely 
ECM-rich tissue. The primary ECM components are collagen and the highly 
negatively charged proteoglycan aggrecan, which account for 20-30% and 10% of 
cartilage mass (w/w), respectively [241]. Aggrecan, in conjunction with chondroitin 
sulfate glycosaminoglycan (CS-GAG), keratin sulfate glycosaminoglycan (KS-
GAG), and hyaluronan (HA) attract water, forming a super-hydrated gel that endows 
cartilage with its ability to absorb loads of up to 20 MPa, and withstand compressive 
strains of 10-40%.  A highly structured (anisotropic) network of collagen fibrils 
functions to provide this hydrogel shock absorber with tensile strength.  As the 
stiffness of the resident chondrocytes is ~1000-fold less than the ECM, they 
essentially do not contribute directly to bulk mechanical properties of the tissue.  
Further, the cartilage ECM fraction appears to be mechanically stable, and largely 
unaffected by freeze-thaw cycles [242], implying that it may be realistic to expect 
this tissue to be mechanically functional post decellularization.   
 
2.5 PREVIOUS APPLICATION OF DECELLULARIZED CARTILAGE 
ECM IN CARTILAGE TISSUE ENGINEERING 
 
There are now a handful of studies outlining the manufacture of scaffolds from 
either pieces or sheets of decellularized cartilage tissue [243-245], and even patents 
describing the decellularization of the entire articular surface [246].  Pivotal 
 68 Chapter 2: The Rationale for Using Microscopic Units of Donor Matrix in Cartilage Defect Repair 
contributions to the development of these concepts began in 1998 with Peretti et al. 
demonstrating that devitalized donor cartilage pieces could be effectively bonded 
together by chondrocytes seeded between pieces [244].   Specifically, 1 mm (by 3x5 
mm) thick slices of ovine donor cartilage were prepared via 5 cycles of 
freeze/thawing to destroy the resident chondrocytes.  Three pieces of devitalized 
tissue were mixed with 106 ovine chondrocytes, with the layered structure initially 
held together with fibrin glue.  Bonding of the donor cartilage continued to improve 
in vivo, with a plateau at 28 days. At this time the fibrin glue had been replaced by 
new cartilage tissue.  Qualitative organization of the new tissue continued to improve 
until day 42 when the experiment was terminated, with some recolonization of the 
donor cartilage slices, although only near the exposed surfaces rather than throughout 
the construct. One of the challenges frequently encountered in cartilage repair is 
failure of the graft, or de novo cartilage, to effectively bond with the adjacent native 
tissue. Thus the observations made by this team, suggesting that donor matrix, and 
presumably native matrix, could be joined in a continuous manner by chondrocyte 
populations seeded between the two surfaces, is particularly promising. 
In the previous study [244] repopulation of the donor matrix was limited, 
resulting in large regions devoid of functional cell populations. Typically, 
chondrocyte migration through dense cartilage matrix is poor, and this is a feature 
partially responsible for the tissue’s limited intrinsic repair capacity.  In fact, 
migration is so poor that in repair procedures, such as mosaicplasty there is 
commonly a border of “dead tissue” at the donor-host tissue interface where the 
lacunae are simply not ever repopulated [157].  Fig 2.1 shows the relative cell: 
matrix volume ratio in cartilage, versus dermal tissue that is commonly utilized in 
acellular repair applications.  The decellularized products are very different, and 
consequently, so is their repopulation potential.  The high matrix content in the 
cartilage tissue makes decellularization challenging, and compromises subsequent 
repopulation [247]. 
Given the limited repopulation potential of decellularized or devitalized 
cartilage donor tissue, more recent efforts focused on exploiting donor matrix in 
tissue engineering applications have had the greatest success when the thickness of 
the donor tissue was reduced.  For example, in the study reported by Gong et al. 
donor tissue dimensions were reduced to 10-30 μm in thickness to enhance cell 
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infiltration.  Specifically, discs of porcine ear donor cartilage matrix were prepared 
by decellularization in sodium dodecyl sulfate followed by lyophilization. 
Suspensions of ovine chondrocyte populations, derived from the ears of new-born 
pigs, were seeded between the discs.   
 
 
Figure 2.1. Decellularized cartilage and dermis and their subsequent repopulation 
with host cells.  
a) Decellularized cartilage with empty lacunae (pink) and dense surrounding matrix 
(purple). b) Chondrocytes (green) attempting to repopulate decellularized cartilage, 
with minimal penetration into the donor matrix and repopulation of lacunae only 
occurring at the periphery (based on Kheir et al. 2011) [28]. c) Decellularized dermis 
with sparse matrix and significant void space. d) Repopulation of decellularized 
dermis with organized zones of fibroblasts (bottom, pink), keratinocytes (middle, 
red) and differentiated keratinocytes (top, brown; based on Nunez et al. 2009) [248]. 
Image reprinted here by permission of the Springer Science+Business Media 
(Appendix D). 
 
 
This strategy enabled the authors to generate cartilage constructs, reported to 
have recovered 87% of the native (ear) cartilage tissue’s mechanical properties, 
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following 12 weeks in vivo incubation subcutaneously in nude mice. The mechanical 
properties of this porcine ear-based cartilage construct were only ~0.015 MPa 
following 4 weeks of in vitro culture and ~4 MPa following an additional 12 weeks 
in vivo culture.  By contrast mature articular cartilage, measured using the same 
methodology, has a Young’s Modulus of approximately 40 MPa [249].  Whilst more 
rigorous mechanical evaluations may have provided a more precise mechanical 
characterizations [250], the available relative comparisons do provide the necessary 
order of magnitude appreciation of the engineered tissue’s potential.  The fragile 
modulus in the final in vivo incubated tissues, and particularly the in vitro cultured 
tissues, suggest that these constructs are not suitable for use in the repair of articular 
cartilage defects.  However, this study provides valuable insight into the utilization 
of decellularized cartilage tissue.  Specifically, this study further demonstrated that 
the repopulation of the donor tissue was a limiting factor.  In the thinner 10 m 
sheets ~60% of the donor tissue lacunae were repopulated, whilst less than 10% of 
donor tissue lacunae were repopulated in the thicker 30 μm sheets.  
The obvious trend towards better outcomes with reduced donor tissue 
dimensions, suggests that additional reductions in donor tissue dimensions will likely 
enhance de novo tissue quality.  An important consideration in the development of 
cartilage repair technologies is whether the objective is to regenerate fully functional 
tissue in vitro for ultimate use in joint resurfacing, or to attempt to enhance more 
modest in situ repair procedures such as Autologous Chondrocyte Implantation 
(ACI) or Matrix-induced Autologous Chondrocyte Implantation (MACI).  In both the 
ACI and MACI procedures a biopsy of cartilage tissue is harvested from a non- 
weight bearing region of the joint in a preliminarily surgery [251].  Chondrocytes are 
isolated from this biopsy and expanded in culture for 2-3 weeks.   In a second 
surgery, the expanded cell population is transplanted into the defect site either 
beneath a periosteal membrane (ACI) [182], or on a collagen gel membrane (MACI) 
[252].  It is critical to appreciate that initial repair tissues following the ACI or MACI 
procedures is essentially only a cell suspension or cells on a collagen gel, 
respectively.  Actual cartilage tissue is regenerated in situ by the transplanted cell 
population over a period of months to years [253].   
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We would argue that, in the near-term, enhanced in situ repair strategies are 
more likely to be clinically achievable than strategies aiming to generate mature 
cartilage tissue in vitro for use in subsequent joint resurfacing.  In such cases, in situ 
application of the donor matrix concept will likely require approaches where the 
donor matrix and donor cells self-assemble into an organized tissue.  More 
sophisticated manufacturing methods, like those reported previously [243-245, 254], 
will likely be more suited for in vitro cartilage construct assembly and cultivation. 
Our team has recently undertaken in vitro and in vivo studies on the self-
assembly of cartilage constructs generated from either mesenchymal stem/stromal 
cells (MSC) or articular chondrocytes in combination with lyophilized donor 
cartilage matrix that has been pulverized into ~2 μm microparticles (so-called 
Cartilage Dust (CD)).  Herein we briefly describe a portion of our in vitro studies 
demonstrating that CD is well integrated into cartilage constructs after only 14 days 
of in vitro culture, and that the CD supplement results in larger tissues having 
enhanced chondrogenic gene expression.  In these studies 200,000 passage 2 articular 
chondrocytes were pelleted in 15 ml falcon tubes (Becton Dickenson) in medium 
composed of High-glucose DMEM (Gibco), 10 ng/mL recombinant human 
Transforming Growth Factor- β1 (TGF-β1) (Gibco), 10−7 M dexamethasone (Sigma), 
200 μM ascorbic acid 2-phosphate (Sigma), 100 μg/ml sodium pyruvate (Sigma), 40 
μg/ml proline (Sigma), 1% ITS-X (Gibco) and 1% PS.  Pellet cultures supplemented 
with 400 g of CD were contrasted against controls without CD.  All cultures were 
maintained in a 5% CO2, 2% O2 atmosphere at 37C for 14 days.  Medium was 
exchanged twice per week.   
Fig. 2.2a shows a phase contrast image of CD alone for size characterization.  
CD particles had an average diameter of ~2 m.  We found that the CD particulate 
supplement added to each pellet culture retained approximately 50 g of GAG after 
being lyophilized, pulverized and washed. The addition of the CD supplement 
resulted in an approximate 2-fold increase in pellet diameter, corresponding to an 
approximate 8-fold increase in pellet volume relative to cell only controls (Fig. 2.2b).  
Fig. 2.2c and d show Alcian Blue GAG staining and haematoxylin nuclei staining.  
CD containing pellets appeared to have greater GAG content, and this qualitative 
assessment was supported by GAG quantification (data not shown).  Critically, there 
was a reasonably uniform distribution of cells and CD, and as the CD particle’s dia- 
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Figure 2.2. Cartilage dust (CD) enhances the quality of cartilage constructs formed 
from articular chondrocytes.  
a) CD particles were approximately 2 μm in diameter. Bar 20 μm. b) CD-containing 
pellets (left) were approximately eight-fold greater in volume than cell-only (right) 
pellets. c, d) Alcian Blue GAG staining and hematoxylin nuclear staining (dark blue) 
of pellet cultures. c CD-containing pellet cultures. CD was evenly distributed within 
pellets. Bar 100 μm. d Cell-only pellets. Bar 50 μm. e Chondrogenic and osteogenic 
gene expression (± Standard deviation) in pellet cultures. CD-containing cultures had 
enhanced chondrogenic gene expression and reduced osteogenic gene expression. 
*Significant difference relative to the chondrocytes–CD group (P<0.05, n04) [25]. 
Image reprinted here by permission of the Springer Science+Business Media 
(Appendix D). 
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meter was less than the diameter of a single cell all donor tissue lacunae were 
exposed and could potentially be repopulated by the supplied chondrocyte 
population.  Supplementation of pellet cultures with CD resulted in a significant 
enhancement of chondrogenic gene expression (Aggrecan, Collagen II and Sox 9) 
and even a moderate reduction in the expression of genes commonly associated with 
hypertrophy (Runx2 and Collagen I) (Fig. 2.2e).  This shift in gene expression is 
perhaps not surprising as similarly prepared cartilage matrix [243] has been 
previously reported to contain growth factors, including Insulin-like growth factor 
(IGF) and TGFβ, known to support cell expansion [255] and chondrogenic 
differentiation [256].   
We reason that the microscopic nature of the CD, and the observed self-
assembly with MSC or chondrocytes, will make this strategy suitable for in situ 
repair strategies where the repair components will likely need to be injected into 
defect sites (see Fig. 2.3).  We envision that CD could be combined with expanded 
chondrocytes or MSC shortly before transplantation via the ACI or MACI 
protocol(s). The microscopic nature of CD should enable the self-assembled 
composite to mould to fit complex defect geometries, unlike prefabricated scaffolds.   
Importantly, the GAG fraction in the CD should enhance the mechanical 
properties of the initial repair tissue, relative to current ACI or MACI approaches, 
which initially lack any functional cartilage matrix.  This alone could revolutionize 
existing therapies, as these strategies are plagued by the fragile nature of the initial 
repair tissue and its extraordinary sensitivity to unintended microtrauma [257].   
It is likely that the CD concept can be extrapolated to include the use of 
cadaveric or xenogeneic matrix recovered from bovine or porcine cartilage, thus 
providing an essentially unlimited supply of donor matrix for human joint repair.  
There are already numerous reports describing the clinical use of other decellularized 
xenogeneic tissues [218], as well as the preliminary development of protocols to 
eliminate immunogenic antigens from xenogeneic cartilage matrix [258]. Whilst it 
should be possible to process donor tissue such that pathogen transfer or 
immunological concerns are minimized, there is a risk that “over-processing” will 
reduce CD matrix content and as wells as its ability to support enhanced 
chondrogenesis.  Studies that contrast theses donor matrix sources and processing 
methodologies will guide future clinical decisions. 
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Figure 2.3. Use of a slurry of CD (pink) and ex-vivo-expanded autologous 
chondrocytes (green) might enable a defect site to be filled, thereby generating a 
more stable initial repair tissue and ultimately achieving enhanced clinical outcomes 
(adapted from Redman et al. [157]. 
Image reprinted here by permission of the Springer Science+Business Media 
(Appendix D). 
 
 
Further innovations might enable CD to be used in conjunction with newer 
single-step repair strategies such as Autologous Matrix-Induced Chondrogenesis 
(AMIC) [259].  In these procedures the surgeon penetrates the subchondral bone 
(microfracture) liberating bone marrow MSC into the defect site, which is then 
sealed with the MACI collagen membrane.  No preliminary surgery or cell culture is 
required for the AMIC procedure making this a potentially versatile and cost 
effective alternative to ACI and MACI.  The addition of CD could enhance the in 
situ chondrogenesis of the liberated MSC in the AMIC process, as well as support 
the formation of a more robust initial repair tissue.   
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2.6 CONCLUSION 
In conclusion, we hypothesize that just as donor matrix has proven to be 
exceedingly valuable in the regeneration of other tissue types, donor cartilage matrix 
will enable similar outcomes in articular cartilage repair if it is supplied in the 
appropriate microscopic dimensions.   
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Chapter 3: Effects of Cartilage Dust on 
Cartilage Formation in in 
vitro and in Ectopic in 
vivo Models 
3.1 ABSTRACT 
 
Articular cartilage injuries can be troublesome and debilitating for patients, and 
also place a heavy burden on health systems and governments, especially in countries 
with ageing populations [118].  Since cartilage lacks an efficient self-repair capacity 
[36], surgical intervention often becomes necessary.  Various treatment methods 
have been developed for this purpose, among which cell-based strategies appear to 
be the most promising.  Autologous chondrocyte implantation (ACI) [260] or matrix-
assisted chondrocyte implantation (MACI) [252] approaches involve the application 
of a slurry of in vitro-expanded chondrocytes, but which are very vulnerable to 
trauma [261] by the time more mature repair tissues are formed.  To tackle this 
problem, decellularized cartilage matrices have been applied as bioscaffolds to 
produce engineered constructs [30, 34, 262].  However, cell infiltration through the 
dense cartilage matrix is difficult.  We, therefore, applied micron-sized cartilage 
particles to investigate cell infiltration and repopulation through the matrix.   
Human articular cartilage was separated from the healthy parts of the 
osteoarthritic joint.  The cartilage was then freeze-dried and powdered into particles 
smaller than 100 µm, but mainly 2 µm in diameter, known as cartilage dust (CD).  In 
the next step, CD particles were added to chondrocyte to form CD-containing pellets.  
The resulting CD-supplemented cartilage constructs were compared in size with the 
cell-only constructs after 2 weeks of culture in chondrogenic differentiation media 
and after 4 weeks of implantation at the backs of SCID mice, respectively, and also 
were assessed through the measurement of glycosaminoglycan (GAG) production, 
chondrogenic and osteogenic gene expressions, histology, and antibody immune-
localization.  
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Results demonstrated that CD was reasonably well-integrated with cells 
following 2 weeks of in vitro culture.  CD-containing constructs produced more 
GAG, both in vitro and in vivo, and chondrogenic as well as osteogenic genes were 
upregulated.  CD-supplemented constructs showed stability in subcutaneous tissues 
of mice after 4 weeks of implantation, while cell-only constructs were either 
degraded or lost.   
In conclusion, incorporation of CD particles with chondrocytes appears to be a 
promising method to boost the vulnerable suspension of cells until the newly 
produced matrix becomes more mature and less vulnerable to trauma. 
 
3.2 INTRODUCTION 
 
Cartilage is a matrix-rich, avascular tissue with a limited self-repair capacity.  
Native, mature articular cartilage consists of more than 95% extra cellular matrix 
(ECM).  Hyaline has the main components of collagen (mostly type II) and 
proteoglycans account for 20-40% of its wet weight [12].  The highly organized 
collagen network, coupled with large proteoglycan aggregates provide the tissue with 
tensile and compressive strength, respectively [99].  It is the ECM that endows 
cartilage with all of its unique mechanical properties.  Chondrocytes, which maintain 
and produce the ECM, represent only about 1% of the tissue volume [40].  
Chondrocyte populations themselves represent only about 1% of the tissue volume 
[263], and they are approximately 3 orders of magnitude softer than ECM, thus their 
direct contribution to tissue mechanical properties is insignificant [264].  This unique 
and highly organized tissue forms and matures over a long period of human 
development, from embryogenesis to early childhood [51, 53, 265].   
Autologous chondrocyte implantation (ACI) [260] and matrix-assisted 
autologous chondrocyte implantation (MACI) [252] have been the most rigorously 
clinically tested, cell-based repair strategies for articular cartilage defects.  In ACI 
therapy, chondrocytes are harvested from a non-load-bearing location on the joint, 
released by enzymatic procedures, and expanded in culture. The expanded cells are 
then used in high densities to repair the primary defect [182, 260].  As a result, the 
initial repair tissue formed following ACI is mostly composed of a cell suspension 
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with little amount of matrix, which is expected to be highly vulnerable to loading 
[261].  Both strategies involve the implantation of expanded chondrocytes into 
defects either beneath a periosteal flap (ACI) or on a collagen membrane (MACI) 
[260, 266], with no functional cartilage matrix.  Whilst both enable modest cartilage 
defect repair, the quality and durability of the regenerated matrix is inferior to native 
cartilage.  Indeed, a major deficiency in ACI/MACI approaches is that the initial 
repair tissue is devoid of cartilage matrix, while mature articular cartilage consists of 
more than 98% ECM) [267] and it is this ECM that endows cartilage with its robust 
tensile and compressive properties [12].  Consequently, matrix-deficient repair 
tissues lack meaningful mechanical properties and are initially fragile.   
Rapid accumulation/regeneration of matrix within the harsh avascular defect 
microenvironment is challenging, and this has motivated attempts to augment cell-
based therapies with mature donor cartilage matrix.  Peretti et al. co-cultured freshly 
isolated chondrocytes with chunks of allogeneic articular cartilage, measured 5 x 3 x 
1 mm in length, width, and depth, respectively [30].  Although devitalized cartilage 
pieces were successfully bonded by chondrocytes, repopulation of the donor matrix 
was only superficial.  Spontaneous repair of cartilage tissue is compromised by the 
inability of chondrocyte to readily migrate through dense cartilage matrix and 
repopulate defect sites.  This same property limited the repopulation of the cores 
within the large devitalized cartilage pieces utilized by Peretti et al.  Chondrocyte 
infiltration was improved in another study by Gong et al. where considerably smaller 
(10-30 μm) devitalized cartilage pieces were utilized [34].  Even within this range, 
there was greater repopulation within the 10 μm donor cartilage pieces relative to the 
30 μm donor cartilage pieces.  These data suggested that donor cartilage matrix may 
have utility in cartilage defect repair but that meaningful repopulation of pieces 
larger than 10 μm was unlikely.  It was reasoned that more effective approaches 
would likely require the utilization of donor cartilage matrix in a microscopic particle 
form that would allow it to be mixed with the cell population and iteratively 
integrated as a filling agent into the de novo tissue over time.  In the present study we 
evaluated both the capacity for the allogeneic donor cartilage matrix microparticles, 
hereafter termed cartilage dust (CD), to be repopulated by human chondrocytes, and 
the ability of this donor matrix to be integrated into the de novo tissue following 
incubation in vivo.   
 Effects of cartilage dust on cartilage formation in in vitro and in ectopic in vivo mode 81 
3.3 MATERIALS AND METHODS 
 
In the following section, the isolation of chondrocytes, production of the CD, 
and formation of cartilage constructs will be explained, and the methods used for 
assessment of the outcomes of CD incorporation will be discussed.  
 
3.3.1 Human articular chondrocyte isolation and expansion 
 
Three consenting patients undergoing total knee replacement surgery donated 
cartilage tissue for the present study.  Ethical approval was granted through the 
research ethics committees of Queensland University of Technology and the Prince 
Charles/Holy Spirit Northside Hospitals in Brisbane in accordance with the 
Australian National Health and Medical Research Council’s Statement on Ethical 
Conduct in Research Involving Humans  (approval number: 1500000794).  Cartilage 
and bone specimens were stored in low glucose Dulbecco’s modified Eagle’s 
medium (DMEM-LG; Gibco) containing 100 U/mL penicillin and 100 μg/mL 
streptomycin (1% P/S, Gibco) at 4 °C until harvest.  Cartilage slices were harvested 
with a scalpel, and rinsed in phosphate buffered saline (PBS).  Before cell harvest, 
the samples were rinsed with phosphate-buffered saline (PBS, Gibco) containing 1% 
P/S.  Articular cartilage tissue was sliced off the macroscopically normal areas 
remaining on the knee joint using a sterile surgical blade, and diced into pieces no 
larger than 2 mm, and washed three times in PBS + 1% P/S.  The diced samples were 
incubated overnight at 37°C in 200 U/mL of Collagenase (Gibco) diluted in DMEM-
LG with 2% P/S and 50 μg/mL gentamicin (Gibco) to release the cells.  A 40 μm cell 
strainer (BD Falcon) was used to remove the undigested tissues.  The cell suspension 
was centrifuged (400 xg, 5 minutes) and washed with DMEM-LG + 1% P/S, three 
times. 
Chondrocytes were seeded in monolayer cultures at 3000 cells/cm2.  
Chondrocyte expansion medium was added, including DMEM-LG, 10% fetal bovine 
serum (FBS; Gibco), 1% Glutamax (Gibco), 40 μg/mL L-proline (Sigma), 200 μM 
ascorbic acid 2-phosphate (Sigma), and 1% P/S.  The cells were grown in a 
humidified incubator under 2% O2 and 5% CO2 conditions.  For primary cells, 50 
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μg/mL gentamicin was also added to the medium.  When cultures approached 80% 
confluence, the cells were trypsynised (TrypLE 0.25%, Gibco) and passaged, giving 
a split ratio of 1:3.  Passage 3 chondrocytes were used in the following experiments.   
 
3.3.2 Preparation of cartilage dust (CD) 
 
Cartilage tissue was obtained and harvested, as mentioned above.  The 
resultant tissue slices were repeatedly (three times) frozen in -80°C and thawed at 
room temperature, and then lyophilized (Christ Alpha 1–2 LDplus) and kept at -80°C 
until use.  Sterilized 3 mm-diameter glass beads (Sigma-Aldrich) and the lyophilized 
cartilage tissue slices were put in a tissue processor (Mini-Bead beater-16, BioSpec) 
set at maximum power until pulverized into finely powdered particles.  The resulting 
particles were suspended in PBS, and passed through a 40 μm cell strainer (BD 
Falcon) to remove particles larger than 40 μm.  The powder was rinsed with PBS, 
centrifuged at 535xg for 5 minutes, and the supernatant discarded to eliminate DNA 
and other cell residues.  This process was repeated three times, and the prepared CD 
was suspended in DMEM HG+ 1% P/S, to prepare a concentrated CD suspension 
(~20 mg/mL).  After agitating the suspension, 20 μL of that was added to each CD-
containing sample, delivering ~400 μg (dry weight) CD per pellet. 
A diluted droplet of CD suspension was put on a glass slide, and a 
monochrome phase contrast image was taken with a Nikon DS-Qi1Mc camera using 
ECLIPSE Ti microscope (Nikon, Japan) at 4X magnification.  Feret’s diameter was 
used to measure the average size of CD particles using ImageJ (NIH, USA).    
 
3.3.3 Pellet formation and chondrogenesis induction  
 
Chondrocytes were redifferentiated as conventional pellet cultures in 15-ml 
polypropylene tubes (LabServ, Thermofisher).  Briefly, 2×105 chondrocytes in 1 mL 
of chondrogenic induction medium (CIM) with or without 400 µg CD were used to 
form a pellet by centrifuging at 400 xg for 5 minutes.  CIM was made up with 
DMEM-HG, including 10 ng/mL transforming growth factor-β1 (TGF-β1, 
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Invitrogen), 100 nM dexamethasone (Sigma-Aldrich), 200 µM L-ascorbic acid 2-
phosphate (Sigma-Aldrich), 100 µg/mL sodium pyruvate (Sigma-Aldrich), 40 µg/mL 
proline (Sigma-Aldrich), 1× ITS+ (Gibco-Invitrogen), and 1% P/S.   
Pellet cultures were incubated for two weeks at 37°C in a 5% CO2 and 2% O2 
atmosphere.  Media was changed twice a week, and supernatants were collected and 
stored at -80C until analysis.  At day 14, half of the samples (with and without CD) 
were harvested, and either stored in -80C or fixed in 4% paraformaldehyde (PFA) 
for further analysis.  The remaining samples were used in subsequent in vivo 
experimentation.  Images of the CD-containing constructs were taken following 4 
days of in vitro chondrogenic induction using scanning electron microscope (Hitachi 
TM 3000).  The steps of the in vitro experiment are depicted as a flowchart in Figure 
3.1.  
 
3.3.4 Quantification of sulphated glycosaminoglycan (sGAG) and DNA content 
 
In vitro constructs harvested at day 14, as well as the input CD, were digested 
with 1.6 U/mL Papain (Sigma-Aldrich) at 60°C overnight to release the sGAG.  The 
sGAG content in CD, in pellets and in the media collected at days 4, 8, 11, and 14, 
was quantified using a 1,9-dimethyl methylene blue (DMB) assay (Sigma-Aldrich) 
[268, 269].  In brief, samples were dispensed into a 96-well clear plate (Nunc, 
Thermo Scientific), DMB dye was added to each well, and the amount of sulphated 
glycosaminoglycans (GAG) was quantified by measuring the colour shift from blue 
to purple at 530 nm and 590 nm in a plate reader (Benchmark Plus plate reader, Bio-
Rad). Shark chondroitin sulphate (Sigma-Aldrich) was used to generate standard 
curves.   
DNA content in the same papain digests was determined ﬂuorometrically, 
using Quant-iT PicoGreen Kit (Gibco-Invitrogen), as per the manufacturer’s 
instructions.  Briefly, following the dispensing of the samples in a black, 96-well 
plate (Nunc, Thermo Scientific), the dye was added and analysed via a plate reader 
(POLARstar OPTIMA, BMG Labtech) at 480 nm excitation and 520 nm emission. 
Standard curves were generated using λ phage DNA (Gibco-Invitrogen). 
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Figure 3.1. Steps of the formation of in vitro engineered constructs +/- CD over 14 
days in vitro culture. 
 
 
 
3.3.5 Relative gene expression analysis 
 
An RNeasy Mini Kit (Qiagen) was used for RNA extraction from the pellets 
and the day 0 chondrocytes.  RNA samples were then reversely transcribed using 
SuperScript III RT (Gibco-Invitrogen).  Real-time quantitative polymerase chain 
reaction (qPCR) was performed using a master mix containing Platinum SYBR® 
Green qPCR SuperMix-UDG (Gibco-Invitrogen).  Using an epMotion 5073 liquid 
handling robot (Eppendrof), primers were dispensed into 384-well reaction plates 
and combined with cDNA samples.  The plates were run in a 7900HT Fast Real-
Time PCR System (Applied Biosystems) using the following cycle parameters: 50°C 
hold  for 2 minutes, then 95°C hold for 3 minutes, followed by 40 cycles of  95°C for 
15 s, and 60°C for 30s.  The primers used (all from Geneworks) are listed in Table 1.  
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Results were analysed using 2−∆Ct method and gene expressions were normalized 
against the geometric mean (GeoMean) of two housekeeping genes – glyceraldehyde 
3-phosphate dehydrogenase (GAPDH) and cyclophilin A [270].   
 
 
Table 3-1. List of sequences of the RNA primers and their amplicon sizes. 
 
 
*also known as bone gamma-carboxyglutamic acid-containing protein (BGLAP). 
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3.3.6 In vivo implantation of cartilage constructs 
 
Animal ethics approval was granted through the Animal Research Ethics 
Committee of Queensland University of Technology and the Prince Alexander 
Hospital, Brisbane (approval number 1000000320) in accordance with the Australian 
National Health and Medical Research Council’s statement on ethical conduct in 
research involving animals.  Six male, 6-week-old, non-obese, diabetic, severe 
combined immune-deficient (NOD/SCID) mice were used in these studies.  Animals 
were anaesthetised by intra-peritoneal injection of ketamine and xylazine.  Under 
sterile conditions in a laminar flow hood, two small incisions were prepared 
subcutaneously on either sides of the back of each mouse, followed by the 
implantation of cartilage constructs (atop and below the same side incision).  A total 
of 24 constructs, 12 with and 12 without CD, were implanted on the right and left of 
the back of the mice, respectively, and the incisions were closed using resorbable 
sutures.  Tissues were permitted to incubate in vivo for 4 weeks, after which time the 
mice were euthanized by carbon dioxide asphyxiation, and the constructs explanted 
for analysis.   
 
3.3.7 Tissue preparation for histology, and antibody localization 
 
Harvested in vitro and in vivo samples were fixed in 4% paraformaldehyde 
(PFA, Sigma) for 30 minutes and, along with the frozen normal cartilage tissue 
(kindly donated by the Bone group at IHBI), were washed in PBS, paraffin 
embedded, and subsequently, 5-µm-thick slices were sectioned using a microtome. 
Tissue slices were adsorbed onto poly-lysine glass slides (Thermo Scientific) and air-
dried, and prepared for staining.  All the slides were observed and imaged after 
staining and coverslipping under Laborlux S microscope (Leitz®) using bright field 
illumination. 
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Alcian blue, and hematoxylin and eosin (H&E) staining 
 
In order to visualize the general morphology, some specimens were stained 
with hematoxylin and eosin (H&E) using an auto-stainer (Leica CV5030).  Paraffin-
embedded slices were put in the auto-stainer, where they were automatically 
dewaxed  in xylene, rehydrated in descending concentrations of ethanol, stained with 
Mayer’s hematoxylin, washed with water, dehydrated in ascending concentrations of 
ethanol, counterstained with eosin, cleared with xylene, mounted, and coverslipped. 
To assess proteoglycan deposition, specimens were stained with an Alcian blue 
solution, consisting of 1% Alcian blue (Sigma-Aldrich) dissolved in acetic acid at pH 
2.5 for 30 minutes and filtered.  Briefly, specimens were de-paraffinised in xylene, 
and re-hydrated in decreasing concentrations (100% to 70%) of ethanol.  Next, the 
prepared slides were covered with Alcian blue for 30 min at room temperature, after 
which they were rinsed with tap water to remove the excess Alcian blue.  Nuclei 
were stained with eosin for 15 seconds.  Slides were mounted by DePex mounting 
medium (BDH Laboratory Supplies, England), and coverslipped.   
 
 
Immunohistochemical (IHC) staining 
 
An indirect immune-peroxidase method was applied for immunohistochemical 
analysis.  First, the specimens were dewaxed in xylene, and rehydrated in descending 
concentrations (100% to 70%) of ethanol.  To block endogenous peroxidase 
activities, samples were incubated with 0.3% hydrogen peroxide (H2O2) for 30 min, 
and rinsed repeatedly in PBS.  For antigen retrieval, samples were incubated with 
proteinases K (DAKO Multilink, CA, USA) for 20 min.  In the next step, non-
specific antigen (Ag) binding sites were blocked with 0.1% bovine serum albumin 
(BSA) and 10% swine serum in PBS.  All of the mentioned procedures were 
performed at room temperature.   
To detect collagen types I and II, sections were incubated overnight at 4˚C in a 
humidified chamber, with optimal dilution of primary antibodies (both 1:100 in 1% 
BSA) for human collagen II and X, raised in rabbit (Abcam).  The next day, after 
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washing twice with 0.3% Triton X-100 in PBS followed by washing once with PBS, 
sections were incubated with the secondary antibody (Cy-3 conjugated anti rabbit 
IgG, Abcam) with the dilution of 1:500 in 1% BSA, at room temperature for 30 
minutes. 
Universal LSAB™+ Kit/HRP (Dako) containing a secondary antibody 
conjugated with horseradish peroxidase (HRP) was applied according to the 
manufacturer’s instructions.  Diaminobenzidine (DAB, Sigma) was used as 
chromogen substrate to visualize antibody complexes, and then the slides were rinsed 
in PBS.  Mayer’s haematoxylin (Sigma-Aldrich) was applied for counterstaining for 
10 seconds, after which the slides were washed under running tap water.  Finally, 
samples were dehydrated with increasing concentrations (70% to 100%) of ethanol 
solutions, cleared in xylene, mounted with DePeX (Gurr; BDH laboratory supplies) 
mounting medium, and coverslipped.  Control samples were also prepared by 
applying 1% BSA without adding primary antibodies. 
 
 
3.3.8 Statistical analysis 
 
All experiments were conducted with n ≥ 7 replicates, with two unique 
biological chondrocyte donors.  The CD was prepared from another cartilage donor.  
The results were analysed by one-way analysis of variance (ANOVA) with Tukey 
post-hoc tests to identify statistical significance (p < 0.05) using SPSS software 
(SPSS Inc., Chicago, IL).  All continuous data are expressed as mean ± standard 
deviation (SD). 
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3.4 RESULTS 
 
3.4.1 CD characterization 
 
Freeze-dried and pulverized cartilage appeared macroscopically as a fine white 
powder that could be separated from culture medium by centrifugation (see Figure 
3.2, A).  Image analysis showed, on average, filtered cartilage particle were 2 µm in 
diameter, with most particles being less than 12 µm in diameter (see Figure 3.2, B 
and C).  There were also particles bigger than 12 µm, although in low numbers.  
 
 
 
 
Figure 3.2. Cartilage dust (CD) characteristics.  
 
(A) Macroscopic view of CD after centrifuging and discarding the supernatant, (B) 
phase contrast image of CD particles. Scale bar is 20 µm and magnification is x20, 
(C) the distribution of cartilage particle sizes with the highest frequency around 2 
µm.   
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3.4.2 Construct formation and maintenance in vitro and in vivo 
 
Cartilage-like tissues formed from 2×105 expanded articular chondrocytes were 
compared with or without 400 µg CD. When forming constructs in vitro, constructs 
containing CD initially formed as a sheet (see Figure 3.3, A).  By contrast, the cell-
only aggregates (no CD) formed well-rounded spheroids by approximately 24 hours 
(see Figure 3.3, B).  After 2 days incubation in chondrogenic induction medium, the 
shape of the CD-containing constructs stabilized into an ellipsoidal geometry.  A 
scanning electron microscope (SEM) image (Hitachi TM 300) taken from a CD-
containing ellipsoidal aggregate at day 4 shows that chondrocytes have infiltrated 
through CD particles, forming a composite cell-CD material (see Figure 3.3, C). 
Following 2 weeks of in vitro cultivation, CD-supplemented and cell-only 
pellets were implanted subcutaneously into dorsal pouches of SCID mice for 4 
weeks, after which the animals were sacrificed, and pellets were harvested.  Unlike 
cell-only pellets, all CD augmented constructs were retrieved at implantation site 
(see Figure 3.3, E).  All of the CD-containing pellets were found at the sites they 
were implanted.  However, only one cell-only construct was recovered and the rest 
were probably digested or degraded in vivo.  The no-CD pellet and CD-containing 
pellets were covered with fibrous tissues, without signs of vascularization (see Figure 
3.3, F).  The inclusion of CD resulted in larger pellets following 14 days of in vitro 
culture (see Figure 3.3, D); the average diameter of pellets containing CD was 2.28 
mm ± 0.2, while this number for cell-only pellets was 1.2 mm ± 0.3.  The difference 
was maintained following 4 weeks in vivo; with the CD-containing constructs being 
approximately twice the diameter of cell-only pellets (see Figure 3.3, E and F).   
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Figure 3.3. In vitro and in vivo cartilage constructs with or without cartilage dust 
(CD).  
 
(A, B) Morphology and size of the chondrocyte pellets after 24 hours chondrogenic 
induction in vitro with (A) or without (B) CD supplementation. CD containing 
constructs formed as a sheet, which curled up later to form an ellipsoid pellets, unlike 
cell only constructs which formed as a sphere; (C) SEM (Hitachi TM 300) view of 
cartilage construct supplemented with CD after 4 days in vitro culture. CD particles 
at the outside surface of the construct are illustrated, which appear like a porous 
scaffold infiltrated by chondrocytes.  Red and black flashes point to larger CD 
particles and cells, respectively; (D) pellets with (on the left) or without (on the right) 
CD after 14 days chondrogenic induction in vitro. CD-containing constructs with 
estimated average diameter of 2.3 ± 0.2 mm (n=4) were bigger in size compared to 
no CD constructs with estimated mean diameter of 1.3 ± 0.3 mm (n=4); (E) cartilage 
constructs containing CD, at the time of explantation, after 4 weeks in vivo 
implantation in mice; (F) Harvested in vivo raised pellets with CD (left) or without 
(right) CD, wrapped in fibrous capsules. The estimated average diameter of CD-
containing constructs was 2.1 ± 0.1 mm (n=4), while the only non-CD containing 
pellet’s diameter was 0.3 mm.  Spaces between lines in A, B, D, and F represent 1 
mm.  
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3.4.3 GAG production and DNA content in constructs 
 
The elution of GAG from the developing tissues was quantified in the medium 
collected at days 4, 8, 11, and 14, and within the harvested tissues at day 14 (see 
Figure 3.4, A).  While a significantly greater amount of GAG was eluted from the 
constructs containing CD, the amount of GAG retained in the aggregates was similar 
in both samples.  However, combining CD with chondrocytes to make cartilage 
constructs increased the total GAG production over 14 days of culture, relative to 
cell-only constructs.  The graph also shows that a burst in GAG release happened in 
day 4 from CD-supplemented pellets, which mainly originated from the added CD, 
rather than the differentiating chondrocytes.  A subtraction of the amount of GAG 
added to the pellets at the start of the experiment showed that the total amount of 
GAG produced by the de novo tissues was considerably higher compared to cell-only 
constructs. 
At day 14, the DNA content of both constructs increased relative to time zero 
(see Figure 3.4, B), demonstrating similar cell proliferation in both conditions.  
Whereas cell proliferation was statistically similar in both in vitro conditions, CD 
supplemented cells produced higher amounts of GAG, possibly due to the presence 
of cartilage ECM. 
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Figure 3.4. GAG production and DNA content by human articular chondrocyte 
pellets in chondrogenic induction media (CIM), with or without cartilage dust (CD) 
supplementation over 2 weeks period, under 2% O2 and 5% CO2 conditions.  
 
Figure A shows the GAG release profile over 14 days determined by the amount  
eluted into the supernatant between medium exchanges, at days 4, 8, 11, and 14.  The 
bar defined as “Total media” represents the cumulative amount of secreted GAG to 
the media at different time points.  The amount of GAG retained within the pellets 
was also determined (shown as “Constructs”).  The de novo total GAG represents the 
cumulative total GAG that either eluted into the medium, or was retained in the pellet 
over 14 days of chondrogenic induction.  In the CD-containing condition, the amount 
of supplemented GAG was excluded from de novo total GAG; Figure B illustrates 
DNA content of 200,000 passaged chondrocytes before chondrogenic induction 
(time zero), along with the DNA content of cartilage pellets with (+) or without (-) 
CD, after 14 days of chondrogenic induction.   
All values are mean ± SD for n = 9 samples.  The experiment was done three times, 
each time with a distinct donor.  *p < 0.05. 
 
 
 94 Chapter 3: Effects of Cartilage Dust on Cartilage Formation in in vitro and in Ectopic in vivo Models 
3.4.4 Relative gene expression of cartilage constructs in vitro   
 
Chondrogenesis and redifferentiation were assessed by measuring the relative 
expression of genes related to chondrogenic and osteogenic differentiation, as well as 
hypertrophy (see Figure 3.5).  Relative to time zero chondrocytes, chondrogenic 
genes, that are aggrecan, Sox9, and collagen II, were significantly upregulated, while 
versican and Runx2 were downregulated in redifferentiated chondrocytes with or 
without CD supplementation.  However, collagen X and osteocalcin were also 
increased compared to non-conditioned chondrocytes.  Collagen I, which is mainly 
found in fibrocartilage and bone, was markedly upregulated in CIM conditioned 
chondrocytes, the expression of which was significantly higher in cell-only 
constructs.  Between two groups of differentiated chondrocytes, there was significant 
upregulation of aggrecan, Sox9, and collagen II, as well as osteocalcin and collagen 
X in CD complemented group.  The overall elevation in the expression of 
chondrogenic genes in CIM + CD group probably indicates the chondroinductive 
effect of CD.  At the same time, the higher expression of collagen X and osteocalcin 
in the CD-supplemented group might imply that CD used in our experiment showed 
some osteo-inductive effects.  Since these genes were also upregulated in cell-only 
pellets compared to expanded chondrocytes, it is likely that some ingredients in the 
CIM have such osteogenic effects. 
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Figure 3.5. Expression levels of chondrogenic, osteogenic, and hypertrophic genes in 
expanded human articular chondrocytes before undergoing chondrogenic induction 
(time zero chondrocytes), or after 14 days in chondrogenic induction medium (CIM) 
with (CIM+CD) or without (CIM-CD) CD supplementation under 2% O2 and 5% 
CO2 conditions relative to the geometric mean of housekeeping genes cyclophilin A 
and GAPDH. 
Figure A compares the expression of collagen I and collagen II, Figure B shows the 
up-regulation of Sox9 and Runx2, Figure C deals with the expression of aggrecan 
and versican, and Figure D depicts the expression of collagen X and osteocalcin 
genes, all after 2 weeks chondrogenic induction in vitro. 
All values are mean ± SD for n = 9 samples.  The experiment was done three times, 
each time with a distinct donor.  *p < 0.05. 
 
 
 
A B 
C D 
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3.5 ASSESSMENT OF MATRIX DEPOSITION AND DISTRIBUTION IN IN 
VITRO AND IN VIVO CONSTRUCTS VIA HISTOLOGY AND 
ANTIBODY STAINING 
 
3.5.1   Hematoxylin and eosin (H & E) and Alcian blue staining 
 
Figure 3.6 illustrates the morphology of normal cartilage tissue (A), as well as 
in vitro and in vivo conditioned constructs (B-E), through H&E staining.  Since 
collagen fibres are very fine and, therefore, hard to be resolved by light microscopy, 
the matrix in normal cartilage tissue appears structureless.  Furthermore, in native 
cartilage (see Figure 3.6, A) chondrocytes are more dispersed compared to all of the 
other immature cartilage constructs shown in that figure (see Figure 3.6, B-E), which 
are highly cellular.  There are some voids in the outer surface of the CD-
supplemented in vitro construct, resulting from the detachment of larger pieces of the 
CD particles during sectioning (see Figure 3.6, C).  In the implanted constructs, the 
pellet containing no CD (see Figure 3.6, D) appears contracted and filled by small 
cells, which are probably mouse cells, while in the CD-containing pellet, dispersed 
islands of matrix can be seen.   
To visualize the GAG deposition, in vitro and in vivo samples were stained 
with Alcian blue, followed by counterstaining of the nuclei with haematoxylin (see 
Figure 3.7).  Normal cartilage tissue stained dark blue via Alcian blue staining, 
indicating the richness of GAG (see Figure 3.7, A).  Both types of in vitro constructs 
(+/- CD) also revealed depositions of GAG (Figure 3.7, B and C), although it was 
much less intense compared to the normal cartilage.   In the CD-containing pellet 
(see Figure 3.7, C), the added particles appeared to be reasonably uniformly 
distributed throughout the construct, and well integrated into the de novo tissue by 
day 14.  There were, however, some voids in the outer surface of the CD-
supplemented in vitro construct, resulting from the detachment of larger pieces of the 
CD particles during sectioning (see Figure 3.7, C).  This integration was obviously 
increased after 4 weeks of in vivo implantation of the pellet (Figure 3.7, E).  While 
the pellets without CD appeared to be more homogeneous in vitro (see Figure 3.7, B) 
than the pellet with CD, they were almost degraded in vivo (see Figure 3.7, D).  In 
both in vitro constructs, cells appeared to have chondrogenic phenotype.   
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Figure 3.6. H&E-stained sections of normal cartilage and engineered cartilage 
constructs with or without cartilage dust (CD) in vitro and in vivo.  
(A) Normal articular cartilage before lyophilisation, with sparse cell lacunas and 
seemingly structureless matrix; (B, C) highly cellular in vitro constructs after 2 
weeks chondrogenic induction without CD (B) and with CD (C); (D, E) In vivo 
constructs after 4 weeks implantation in subcutaneous pouches on the back of the 
mice, the explanted without CD pellet (D) appears to be degrading and filled with 
cells, while the CD-supplemented pellet (E) appears to have more mature matrix. 
Scale bars represent 100 µm, and images magnifications are x10. 
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Figure 3.7. Distribution of GAG detected by Alcian blue, in normal cartilage and 
engineered cartilage constructs with or without cartilage dust (CD) in vitro and in 
vivo.  
.  
(A) Normal articular cartilage before lyophilisation, with sparse cell lacunas and 
seemingly structureless matrix which is rich in GAG. The deposition of GAG 
reduces in the transitional layer between the cartilage and its underlying bone; (B, C) 
highly cellular in vitro constructs after 2 weeks chondrogenic induction. The pellet 
without CD (B) shows homogeneous GAG deposition, and the pellet with CD (C) 
illustrates CD particles reasonably homogeneously distributed in the matrix; (D, E) 
In vivo constructs after 4 weeks implantation in subcutaneous pouches at the back of 
mice. The explanted without CD pellet (D) appears to be shrinking and filled with 
cells, while CD-supplemented pellet (E) appears to have more mature and 
homogeneous matrix. Scale bars represent 100 µm, and image magnifications are 
x10. 
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The spherical shape of the cells could have been a sign of redifferentiation of 
passaged chondrocytes after induction in three dimensional (3D) culture conditions.  
This finding was in line with upregulation of chondrogenic gene expression shown in 
RT-PCR results. 
 
3.5.2 Antibody localization through IHC  
 
To detect the collagen II and collagen X content of samples, 
immunohistochemical staining by polyclonal antibody was performed.  Figure 3.8 
shows that, as expected, normal cartilage tissue is rich in collagen II (see Figure 3.8, 
A).  In vitro constructs, either with or without CD supplementation, stained positive 
for collagen II (see Figure 3.8, B and C), especially in the outer surfaces of both 
constructs, although remarkably less intense compared to the native cartilage tissue.  
There are some voids in the outer surface of the CD-supplemented in vitro construct, 
resulting from the detachment of larger pieces of the CD particles during sectioning 
(see Figure 3.8, C).  
For the in vivo constructs, the staining seems to be  almost negative for 
collagen II in the area of degrading cell-only pellet (see Fig 3.8, D), while CD-
containing explant (Fig 3.8, E) shows some areas of more intense positive staining, 
possibly related to newly deposited collagen II.  In the CD supplemented explant, 
some islands of less cellular matrix are recognizable which are stained positive but 
are not so intense for collagen II (see Fig 3.8, E), and might have indicated remnants 
of degrading CD particles integrated into the newly forming tissue, since a normally 
longer period was expected for the neo-cartilage tissue to be formed and matured. 
Physiologically, the cartilage tissue lacks collagen type X, and expectedly this 
type of collagen was not detected in the normal cartilage sample (see Fig 3.9, A).  
However, in vitro constructs stained positively for collagen X (see Fig 3. 9, B and C), 
seemingly more intense in the CD-supplemented pellet.   
The staining became more intense after implantation (see Figure 3. 9, D and E), 
especially in the remnant of the construct without CD (see Figure 3. 9, D).  There 
were areas in the CD-supplemented explant, which stained negative (grey) for 
collagen X, probably indicating degrading CD particles (see Figure 3. 9, E). 
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Figure 3.8. Distribution of collagen type II detected by polyclonal antibody raised in 
rabbit. 
(A) Normal articular cartilage was intensely stained for collagen II; (B, C) In vitro 
constructs after 2 weeks chondrogenic induction: the pellet without CD (B) stained 
positive, especially in the outer surface of the pellet, for collagen II, so did the pellet 
supplemented with CD (C), in which some voids were noticeable due to detachment 
of the larger CD particles during sectioning; (D, E) In vivo constructs after 4 weeks 
implantation in mice: the explant without CD (D) was mostly degraded, and its 
remnant was pale for collagen II staining, while in the explant with CD (E) there 
were some areas of intense staining, along with areas of pale staining probably 
indicating degrading particles of CD integrated with the newly forming tissue.   
Scale bars represent 100 µm, and image magnifications are x10. 
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Figure 3.9. Distribution of collagen type X detected by polyclonal antibody raised in 
a rabbit.  
(A) Normal human articular cartilage was found to be negative for collagen X; (B, C) 
chondrocyte pellets after 2 weeks chondrogenic induction in vitro: construct without 
CD (B) showed pale positive staining for collagen X, which was also visible in the 
CD-supplemented pellet (C), along with some areas of more intense colouring; (D, 
E) cartilage constructs after 4 weeks of implantation in mice:  
(D) while explant without CD was mostly degraded, and its remnant stained highly 
positive for collagen X, CD-supplemented explant (E) appeared to be less cellular 
with both areas of positive and negative staining for collagen X. 
Scale bars represent 100 µm, and image magnifications are x10.   
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Finally, Figure 3.10 shows stained tissues with different staining methods together. 
 
 
 
 
 Figure 3.10. Stained sections of normal cartilage, as well as in vitro and in vivo 
made constructs, with different types of tissue staining. 
Columns from left to the right illustrate different staining for normal cartilage, cell-
only in vitro constructs (in vitro -CD), CD supplemented in vitro constructs (in vitro 
+CD), cell-only in vivo constructs (in vivo -CD), and CD supplemented in vivo 
constructs (in vivo +CD), respectively. 
Scale bars represent 100 µm, and image magnifications are x10.   
 
 
3.6 DISCUSSION 
 
The beneficial effect of applying native ECM in cartilage tissue regeneration 
has been reported in a number of studies [30, 34, 64, 262, 271-274].  Despite the 
method being applied to process the tissue, incorporation of decellularized native 
tissue appears to be promising in regenerative medicine [26].  Peretti et al. 
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demonstrated that lyophilized donor cartilage tissue could be used to make scaffolds 
for chondrocyte culture and the formation of cartilage-like tissues [30].  However, in 
their constructs it was not possible for the cells to penetrate into the large donor 
matrix pieces and, thus, there remained large areas of the tissue not populated by 
cells or fully integrated into the de novo tissue.  In fact, the limited intrinsic repair 
capacity of cartilage to some extent is related to the tissue’s dense matrix, through 
which chondrocyte or MSC migration is poor [28].  The occurrence of a border of 
“dead tissue” commonly formed at the interface of host and donor tissue in treatment 
procedures such as mosaicplasty is due to this limited cell migration, so that most of 
the lacunae are never repopulated [157].  To further enhance the repopulation of 
dense cartilage matrix, reduction of the thickness of decellularized tissue was 
considered.  For instance, Gong et al. reported that cell migration and repopulation 
were enhanced in thinner (10-30 μm) cartilage pieces [34].  Therefore, we 
hypothesized that with further reduction in the thickness of decellularized cartilage, it 
would be possible to apply these micron-sized particles as an ECM derived scaffold 
material with articular chondrocytes, to regenerate a more mature tissue in vitro, and 
ultimately in vivo.   
 
3.6.1 Cartilage dust characterisation 
 
Application of decellularized ECM materials in tissue engineering has been on 
the rise in the recent years.  Normally, the tissue undergoes different stages of 
processing with enzymes and chemical agents, which usually results in a scaffold 
with inferior structure or composition compared to the original tissue.  Our tissue-
processing method included physical disruption of the donor cartilage matrix and 
washing of the disrupted tissue with PBS.  As a result, the individual collagen fibres 
were expected to remain intact, even though their overall structure and organization 
might have been destroyed.  Further, given the average diameter of human articular 
chondrocytes is less than 20 µm, using decellularized cartilage particles in a size 
range from 1 to 40 µm made infiltration and repopulation of the ECM-derived 
material is more efficient.  Minimal processing of acellular tissues is preferable as 
this reduces the depletion of growth factors and/or other biologically active 
molecules [275] contained within the original tissue [224, 276].   
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 Both decellularization and recellularization of the articular cartilage are 
challenging, due to its dense ECM [24].  Several protocols have recently been 
developed for the decellularization of articular cartilage and facilitation of its 
following repopulation, each with some advantages and disadvantages [224, 276].  In 
a recent study, for example, channels were made by flat-ended needles in the depth 
of provided cartilage discs [277].  The channels appeared to facilitate the penetration 
of enzymes and chemical agents applied for decellularization through the tissue, as 
well as subsequent infiltration of the cells.  It was claimed that the protocol reduced 
90% of the DNA content of the final products, with little change in the collagen 
structure or content [277].  However, compressive properties were adversely affected 
by the protocol since the GAG contents of the scaffolds were almost completely 
abolished.   
There are some steps added to decellularization protocols to reduce the DNA 
content of the processed tissues.  This reduction could be achieved to different 
extents, probably related to the type and concentration of the given agents, as well as 
the duration of their use.  For instance, by using sodium dodecyl sulphate (SDS) as a 
decellularization substance, the DNA content of the cartilage tissue was reported to 
decrease as low as 99% [28].  However, this near complete removal of the DNA was 
achieved following a long duration (6 days) of washing the tissue in a 0.1% SDS 
solution.  The application of a stronger solution of SDS (0.2%) was able to reduce 
the incubation time to 8 hours; however, genomic DNA removal was not as efficient 
as the former protocol (only 40% decrease in DNA content) [278].  Hyaluronidase is 
usually applied in some protocols to achieve a porous scaffold by removing the GAG 
content of the tissue, which consequently facilitates DNA removal, as well as 
penetration of the cells and recellularization of the given scaffold [277, 279].  This 
step, however, has a negative effect on the compressive strength of the final product.  
Further, it has been reported that even the application of SDS by itself (without 
hyaluronidase) could significantly reduce the GAG content in the processed tissue 
[28, 278]. 
Our method for preparing decellularize cartilage particles was simple and 
efficient.  One potential limitation associated with minimal processing methods could 
be the retention of double stranded, nuclear and mitochondrial DNA within the donor 
CD, which could potentially invoke an immune response in the host [280].  Natural 
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chondrocytes’ lacunae have dimensions estimated to be 20-30 µm [281].  In our 
experiment, therefore, pulverization of the donor matrix into particles with the main 
diameters around 2 µm was expected to expose most of the cellular material, and 
most of the DNA would be lost, and subsequently rinsed off from smaller particles.  
Although there was still residual DNA content in the CD, it appeared to be 
insignificant; there was only 1.6 ng DNA/100 µg of CD (n=4, SD=0.16).  Previous 
studies have shown that DNA masses less than 50 ng dsDNA in each mg dry weight 
of the processed ECM do not elicit an immune response [224, 280, 282].  In our 
study, 400 µg   mass of CD only contained ~40 µg GAG (n=4, STDEV=9.77).  Thus, 
we expect that this minimal processing should have been sufficient for the tissue like 
cartilage, which has a low cellularity, and which has been pulverized to expose 
cellular material.   
Powdered decellularized cartilage has been used in previous studies.  In one 
experiment, articular cartilage was crushed into a fine powder, followed by 
decellularization, making suspension, and lyophilisation.  The resulting powder was 
then cross-linked in a mould to make a porous scaffold into which cell migration was 
facilitated [32, 33].  The difference between the GAG amount per mg dry weight of 
the powdered cartilage before and after decellularization was found to be negligible.  
However, the GAG amount was not measured before and after making the powder to 
determine whether grinding the cartilage had any adverse effect on the GAG content.  
Indeed, grinding has been intentionally undertaken to extract the GAG content of the 
cartilage, so, this could have happened in this study as well.  Further, using a cross-
linker makes the duration of the degradation longer, which could increase the risk of 
inducing inflammatory reactions.  Our study did not use any chemicals or enzymes 
that are normally applied in either decellularization or cross-linking processes, in 
order to to prevent the adverse effects of the residues of these agents.  Nuclear 
residues were also efficiently reduced to an acceptable level, simply through 
pulverizing and subsequent washings, confirmed by DNA quantification assay.  
Nevertheless, we found that pulverizing cartilage into microparticles depleted (but 
did not abolish) the GAG content of the matrix, which might be related to washing 
rather than pulverizing the tissue, since we also found that keeping the CD 
suspension causes the GAG to be gradually released into the liquid.  For this reason, 
CD suspension had to be prepared freshly for each experiment.  It should be noted 
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that any type of processing method can change the original tissue’s structure or 
composition to some extent [276], which should be weighed against the beneficial 
effects of the final product in tissue regeneration.    
 
3.6.2 GAG and DNA assessments 
 
Human articular cartilage ECM mainly consists of GAG and collagen type II. 
Since the compressive strength of articular cartilage is provided by its GAG content, 
enhanced GAG production is a key requirement to verify the effectiveness of the 
engineered cartilage tissue [283]. It was shown that chondrocyte redifferentiation and 
GAG secretion were enhanced in hypoxic (2% O2) culture conditions [284].  
Therefore, this oxygen concentration was chosen for this study. 
  Routinely used decellularized protocols inevitably result in bioscaffold 
materials with inferior physical and chemical properties compared to the native tissue 
[217].  For example, in one study, histologic staining assessment of a 
decellularization protocol showed that following the first cartilage treatment with 
trypsin, most of the tissue’s GAG content was lost, and after multiple enzymatic 
procedures the ECM-derived scaffold material was mostly collagen-based, and no 
GAG remained in the final product [285].  Since our method used no enzyme, and 
decellularization steps were done physically and mechanically through lyophilisation 
and pulverization, it was expected that ECM composition and structure would not 
have changed dramatically.  GAG quantification and histology assays confirmed the 
presence of GAG in the CD particles, although these were lower than the normal 
cartilage. 
A standard measure of artificial cartilage construct quality is the quantification 
of GAG content.  Figure 3.4 (A) shows that there was significantly more GAG 
content in the media secreted from the constructs that contained CD.  While a 
significantly higher amount of GAG was eluted from the constructs containing CD, 
the amount of GAG retained in the aggregates was similar in both samples.  
However, combining CD with chondrocytes to make cartilage constructs 
significantly increased the GAG production over 14 days of culture, relative to cell-
only constructs.  In other words, although a large portion of the GAG released into 
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media by CD-supplemented aggregates was eluted from the CD, especially in the 
earlier stages of induction, a significantly higher amount of GAG was produced by 
chondrocytes in CD-augmented cultures, which was calculated by deduction of the 
amount of GAG added as CD from total GAG collected from media and CD 
containing constructs.  The increase in total GAG production in CD supplemented 
pellets, therefore, might imply the beneficial effect of the addition of decellularized 
cartilage matrix particles to the in vitro cultivated pellets, and is consistent with the 
upregulation of chondrogenic genes compared to cell-only pellets.  Further, at day 
14, DNA content of both constructs almost doubled relative to time zero 
chondrocytes (see Figure 3.4, B).  Whereas cell proliferation was statistically similar 
in both in vitro conditions, CD-supplemented cells produced a higher amount of 
GAG/DNA.  This suggests that CIM+CD interact synergistically to enhance de novo 
GAG production from the chondrocytes in the construct.  This finding is promising 
as the CD could be used temporarily as matrix filler, and may also contribute to long-
term regeneration of cartilage matrix.     
Importantly, bone has been engineered by embedding either equine MSC or 
chondrocytes in a hydrogel, with or without cartilage particles resulting from an 
equine healthy joint [286].  In this study, formation of a cartilage template was 
stimulated in MSC group in vitro, by adding cartilage ECM-derived particles, while 
addition of the particles adversely affected the amount of GAG produced by the 
chondrocyte group.  After subcutaneously implanted in rats, the GAG content of both 
chondrocyte-laden constructs, either with or without the particles, was decreased 
compared to before implantation.  However, cartilage-derived particles were 
produced after several steps of mechanical and chemical procedures, which might 
have resulted in over-degraded collagen type II.   
Elution of GAG to the medium commonly occurs in chondrogenesis 
experiments in vitro [287].  It should be noted that collagen type II is as important a 
constituent of articular cartilage as proteoglycans.  Collagen network forms cartilage 
structure and has a key role in the tissue function.  Therefore, cartilage repair 
outcome highly depends on the integration of collagen fibrils [288].  Networks of the 
cross-linked collagen fibrils are not only responsible for cartilage’s tensile strength 
[289], but they also entrap macromolecules within the tissue to form an insoluble 
matrix [290].  Typically, compared to mature articular cartilage, tissue-engineered 
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cartilage constructs suffer from a remarkably lower amount of collagen, and their 
produced collagen micro-fibrils are normally not fully assembled to form thick fibrils 
[291].  This relatively loose structure of collagen network in the nascent cartilage 
tissue may play an important role in GAG release into culture medium [287], which 
might also have happened in both culture conditions in our study.  In vitro GAG 
elution also might be explained, in part, by the probable lysis and degradation of 
proteoglycans, similar to normal protein turnovers in the body [292], which could 
consequently result in the loss of GAG from cartilage construct into the medium.  
This could be the case in our study, especially in the CD-augmented pellets.    
 
3.6.3 Gene expression profile 
 
Direct regulation of collagen type II gene is known to be done by Sox9 [293].  
It is known that chondrocytes expanded in 2D surfaces lose their chondrogenic 
phenotype (de-differentiation), a process which can be reversed by a few methods, 
such as culturing them in 3D environments [7].  This redifferentiation process is 
recognized by the higher expression of chondrogenic genes, that is, Sox9, aggrecan, 
and collagen type II.  Upregulation of these chondrogenesis-related genes in 
conditioned chondrocytes, either with or without CD supplementation, compared to 
day zero chondrocytes could indicate redifferentiation of passaged chondrocytes in 
3D environment of pellets and in chondrogenic inducted media.  This increase was 
significantly greater in chondrocytes redifferentiated in the presence of the CD 
particles, and probably implies the beneficial effect of CD incorporated into 
chondrocyte aggregates, in terms of inducting chondrogenesis.  Dedifferentiated 
chondrocytes are able to redifferentiate, and regain their specific phenotype, in high 
density and 3D culture conditions, although after passage 5 this ability becomes 
significantly limited [294, 295].  Passaged two chondrocytes were applied in our 
experiment, so it was expected that our expanded chondrocytes were able to regain 
their chondrogenic phenotype after differentiation in a 3D environment.  Our finding 
is consistent with a recent study in which dedifferentiated chondrocytes that were 
expanded in a 3D hybrid agarose matrix containing homogenized cartilage ECM 
soluble factors regained their normal phenotype [283].  It is known that using 
chondrogenic induction medium [296, 297], 3D environment [7, 9], and hypoxic 
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atmosphere [298] help de-differentiated chondrocytes to re-gain their chondrogenic 
phenotype.  Our experiment was performed under all of these situations, 
(chondrogenic induction medium, 3D environment, and hypoxia), so re-
differentiation in pelleted chondrocytes was expected in our experiment.   
On the other hand, in addition to chondrogenic genes, collagen I gene 
expression was higher in both inducted groups compared to the expanded 
chondrocytes, especially in pellets lacking CD.  This type of collagen is found 
abundantly in bone and fibrocartilage, but in very small amounts in hyaline cartilage 
[186].  Importantly, ratios of collagen II/collagen I and aggrecan/versican are 
considered as cell differentiation indexes [299].  This shows the importance of both 
collagen types in defining the degree to which the cells are differentiated.  In other 
words, the more differentiated the cells, the higher the expression of collagen II and 
aggrecan, and the lower the expression of collagen I and versican.  Interestingly, the 
cell differentiation indexes have been shown to be higher in normal chondrocytes 
compared to OA-affected cells [299].  In our experiment aggrecan and versican 
genes were significantly upregulated and downregulated, respectively, in both 
chondrogenically induced chondrocytes compared to expanded chondrocytes.  As a 
result, the ratio of aggrecan/versican increased, which was in favour of re-
differentiation.  Collagen type II gene expression was also markedly higher in both 
differentiated groups compared to time zero chondrocytes.  However, the expression 
of collagen type I was also significantly higher in chondrogenically differentiated 
chondrocytes.  In contrast, collagen type II/collagen type I ratio increased in both 
differentiated groups.  Upregulation of collagen I gene expression is usually an 
indication of fibroblastic or osteoblastic differentiation.  The upregulation of collagen 
type I, while all the chondrogenic related genes were highly upregulated could be 
explained by the application of chondrocytes isolated from an OA-affected joint, 
which will be further discussed later in this discussion.  An increase in the ratio of 
collagen type II/collagen type I, however, was much higher in the cell-only group 
compared to the CD-supplemented one, which could suggest the beneficial effect of 
adding CD to the pellet in regulating the expression of collagen type I.  
Cell dedifferentiation during the first 2 weeks of the tissue culture was reported 
following the seeding of porcine nasal chondrocytes in a decellularized nasal 
cartilage scaffold, accompanied by an increase in cell numbers and a higher 
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expression of collagen type I and versican, after which time there was no more 
additional increase in the cell numbers, and the dedifferentiation trend was reversed 
[281].  This was in line with another study demonstrating that an increase in cell 
proliferation, along with a decrease in matrix production was observed in seeded 
chondrocytes onto 3D scaffolds, but the ratio was reversed after reaching a certain 
cell density [300].  An increase in cell number and a higher expression of collagen 
type I were also observed in our experiment.  Longer culture duration might change 
the low ratio of collagen type II/ collagen type I, in favour of redifferentiation. 
Hypertrophy and osteogenesis-related gene expression profiles (collagen type 
X and osteocalcin) were also significantly upregulated in CD-supplemented 
constructs, and in both conditions compared to time zero chondrocytes.  Collagen X 
upregulation normally happens during the process of endochondral ossification [47].  
Therefore, upregulation of this hypertrophic gene, especially along with 
simultaneous upregulation of collagen type I, might indicate the trend of 
chondrogenesis toward ossification in both culture conditions, at least in some 
chondrocytes.  The increase in collagen X gene expression could be partly because 
both cultured chondrocytes and lyophilized cartilage were isolated from osteo-
arthritic joints harvested from elderly donors/joints suffering from the advanced 
stages of OA, especially considering that the expression was greatest in the CD-
supplemented cultures.  It has been shown that hypertrophy-related genes in those 
chondrocytes are rather high [301], while normal articular cartilage cells do not 
express collagen X [47].  Moreover, hypertrophic and osteogenic gene expressions 
appear to be somehow upregulated in the inner zone of articular cartilage, which is in 
vicinity of subchondral bone.  Because in this study we utilized full-thickness human 
cartilage tissue to generate CD or exploit chondrocytes, upregulation of collagen type 
X would be predictable.  Applying non-osteoarthritic cartilage and/or isolation of the 
middle zone of articular cartilage to make CD might minimise this effect.  Such an 
outcome may be especially valuable as the chondrogenic potential of chondrocytes 
derived from OA patients remains controversial [299, 302, 303].  Monolayer 
expansion of chondrocytes before differentiation could have also taken part in this 
phenomenon.  However, given that time zero chondrocytes showed less expression 
of collagen X, other factors might also have played roles in driving chondrogenesis 
to ossification. 
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It was also shown that chondrocyte’s phenotype and morphology could be 
influenced by the type of scaffold chosen for the tissue engineering.  For example, 
chondrocytes cultured on collagen type I matrices tended to show fibroblastic-like 
behaviours, with a higher proliferation rate and lower GAG synthesis [107], while a 
superior environment could be provided for chondrocytes by type II collagen 
scaffolds to produce hyaline cartilage [281].  The cartilage derived from an OA-
affected joint, and the CD made from that cartilage might also have different 
properties compared to a cartilage harvested from a healthy joint, which could 
influence the chondrocytes to choose more osteoblastic or fibroblastic-like features.  
 
3.6.4 Cartilage dust and cartilage constructs 
 
CD-supplemented constructs were almost double the size of cell-only 
constructs after 2 weeks of in vitro culture.  The addition of CD to the pellets and the 
following volume increase implies that it might be beneficial to apply CD to increase 
the matrix content of the engineered constructs within a short time.  Further, 
depending on the size of a given defect, an average of 5-30 million chondrocytes are 
required in ACI to fill the lesion [304].  Since approximately 4.5x105 cells could be 
isolated from a 100 mg biopsy taken from the articular cartilage in a patient older 
than 40 years, in vitro cell expansion is essential to reach the required number of 
chondrocytes for implantation [305].  The addition of CD, therefore, could also result 
in requiring less numbers of cells in cell-based tissue regeneration methods, which 
means requiring less numbers of expansions, and, therefore, better cell qualities to 
repair a given defect. 
 After 14 days of in vitro cultivation, CD-supplemented and cell-only pellets 
were implanted subcutaneously in the dorsal subcutaneous pouches of SCID mice for 
4 weeks.  Although this in vivo site does not mimic the complicated 
microenvironment of the human articular joint nor its load-bearing environment, it 
could give a good insight into the constructs’ capacities and behaviours using more 
cost-effective and more accessible animals.  Indeed, normally many of the tissue 
engineered constructs are initially implanted in immunodeficient murine models to 
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be assessed in vivo without being rejected, and before moving to defect models in 
larger animals [306].   
Mice were sacrificed after 4 weeks of in vivo implantation, and pellets were 
harvested.  All of the explants were wrapped in fibrous tissues, without macroscopic 
signs of vascularization.  While all CD-augmented constructs were reliably located in 
similar positions in which they were initially implanted, just one cell-only pellet 
could be retrieved.  This might be indicative of the superior mechanical properties of 
CD-supplemented constructs.  The loss or resorption of cell aggregates has been 
previously reported [91], although the pellets in these previous studies were formed 
from mesenchymal stromal cells (MSC) rather than articular chondrocytes, as in our 
study.  In our approach, CD containing constructs were larger and more stable 
following in vivo culture, relative to cell-only constructs. 
The engineered constructs were implanted in vivo for 28 days.  Since our aim 
was to assess the incorporation of CD particles rather than the production of a mature 
tissue, 4 weeks of in vivo implantation was performed.    It was reported that cell 
infiltration into the entire depth of the decellularized cartilage could take 6 weeks of 
culture in vitro [281], or 3 months of implantation in nude mice [28].  This is 
considered a relatively short time frame in cartilage studies, given that cartilage 
tissue matures over a long period of time.  Indeed, prolonged tissue culture is needed 
for the formation of engineered cartilage tissue comparable to native cartilage [307].  
Further, sudden environmental changes due to transferring constructs from in 
vitro cultures to in vivo might cause cells to behave unpredictably over the early 
stages of the implantation.  For example, in a study in which cartilage constructs 
were implanted subcutaneously in nude mice, [3H] thymidine uptake was ceased by 
chondrocytes over 4 weeks post-implantation, after which time its uptake was 
gradually increased from day 28 to the end of the experiment (day 42) [30].  Longer 
implantation periods would be beneficial to track possible changes in the constructs 
and their maturation trend, rather than investigating the incorporation of CD particles 
into the constructs. 
  Chondrocytes could be distinguished histologically in all in vivo constructs 
supplemented with CD, and in very low numbers in the remnants of the cell-only 
pellet.  Other than chondrocytes, there were a large number of smaller cells with 
elongated nuclei in both types of in vivo constructs, which probably originated from 
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the mice.  Some of these cells were visible around the islands of intact matrices 
within the CD-supplemented constructs.  At this stage, it is not clear if the matrix 
formed in vivo was totally produced by human chondrocytes or also by mouse cells, 
although bigger degrading CD particles were still visible.  Further investigation of 
the differential diagnosis of the cells, for example, by using labelled chondrocytes 
could shed light on this issue. 
Immunohistochemical staining of native cartilage tissue was negative for 
collagen X.  The staining for both in vitro constructs, however, showed signs of 
collagen X deposition.  This finding was in line with the upregulation of collagen X 
gene expression in vitro, performed by RT-PCR.  However, it has been reported that 
pelleted chondrocytes, even if they are implanted in an ectopic site in mice, have a 
stable phenotype, and do not undergo hypertrophy [308], which is in contrast to our 
observation.  This difference could partly be explained by the source of chondrocytes 
and CD, which were extracted from OA cartilage, or the xenogeneic source of the 
chondrocytes in these experiments, which are likely to behave differently from 
normal human chondrocytes [306]. 
Although collagen X staining for in vivo implanted constructs was positive in 
some areas of the CD-containing group (see Figure 3.9, D), it was substantially more 
intense in cell-only pellets (Figure 3.9, E), suggesting quicker trend of ongoing 
hypertrophy and ossification, signs of which seemed to have started in the in vitro 
cultured pellets.  This finding was inconsistent with the results of some studies in 
which chondrocyte-only pellets remained stable in vivo, and did not show signs of 
hypertrophy or dedifferentiation [91, 309, 310], although healthy human or porcine 
chondrocytes were used in these experiments.  It has been realized that chondrocytes 
derived from various animal species biologically behave differently from human 
chondrocytes [306].  There are also studies reporting that expanded adult human 
articular chondrocytes do not retrieve 100% of their phenotype after a few population 
doublings.  One group, for example, showed that 4-6 population doublings resulted 
in the loss of chondrocytes’ phenotype stability and cartilage production in vivo 
[311].  They also reported that, depending on the parity between micro-
environmental situations and phenotype stability, human articular chondrocytes were 
able to generate various tissues other than cartilage, including skeletal muscle, bone, 
adipocytes, and fibrous tissue.  After injection into nude mice muscle, early passaged 
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chondrocytes produced cartilage, while late passaged chondrocytes formed mainly 
fibrous tissue, along with some muscle tissue [311].  This was likely to be the case in 
our experiment, since we used cartilage and chondrocytes derived from OA-affected 
joints, and therefore the CD-supplemented explants consisted of both collage II and 
X. 
 
3.6.5 Cell and CD sources 
 
We used human articular chondrocytes, and also prepared CD from elderly 
patients suffering from the advanced stages of OA.  The application of chondrocytes 
derived from OA-affected joints for tissue regeneration and repair is a highly 
controversial issue.  For example, one study showed that OA chondrocytes expressed 
VEGF, which has a key role in angiogenesis, and its receptor (VEGFR), both of 
which were not observed in normal chondrocytes and were known to mediate 
destructive processes seen in OA [312].  In another study, collagen type II gene 
expression was downregulated, in accordance with the severity of the disease [313].  
Interestingly, even non-affected and OA-affected cartilages within the same joint 
were reported to have distinct gene expression patterns [314]. 
Further, chondrocyte functions, such as proliferation, GAG production, 
collagen deposition, and the response to bioactive factors also decrease with ageing 
[305, 315, 316].  Indeed, cartilage tissues derived from older specimens happen to be 
thinner and stiffer, with lower cell density and less permeability [317].  As OA is 
considered a disease of the elderly, chondrocytes derived from an OA-affected joint 
are basically aged chondrocytes with features probably inferior to young 
chondrocytes.  It is known that GAG content of articular cartilage deteriorates with 
age.  In a study on 30 cadavers, GAG concentration and even the individual 
proportion of the lateral femoral head varied in an age range from infancy to 70 
years. While half of the dry weight of the cartilage consisted of GAG, this amount 
reduced to 15% in adults [318].  Cartilage tissues used in our experiment were all 
derived from OA affected joints in elderly patients aged 63, 72, and 86 years old.  
Using cartilage from healthy young donors, either from allogeneic or exogenous 
sources could result in more GAG production and, therefore, superior compressive 
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strength.  Dozin et al. investigated metabolic properties of juvenile, senile, and OA 
human articular chondrocytes [319].  Metalloproteinases were highly active in OA 
chondrocytes. Cell morphology and proliferation rates, as well as the biochemical 
properties of the normal aged chondrocytes were found to be more comparable to 
OA chondrocytes, than young chondrocytes [319].   
On the other hand, Stoop et al. showed collage types I and II gene expression 
patterns were statistically similar in expanded normal and OA-affected chondrocytes.  
After implantation in SCID mice; moreover, cartilage explants produced by OA 
chondrocytes found to be rich in proteoglycan and containing collagen type II were 
comparable to the constructs formed by healthy chondrocytes.  Therefore, they 
concluded that OA chondrocytes' application in ACI treatments would be permissible 
[303].  In another study, the risk of producing hypertrophic cartilage did not appear 
to be raised in OA chondrocytes [320].  It was also reported that the proliferation 
rate, as well as proteoglycan production were comparable in healthy and OA-affected 
chondrocytes, and collagen production seemed to be less [321].  Our findings, 
however, appeared to be consistent with those studies that did not supported the 
application of OA-affected tissues or chondrocytes. 
Chondrocytes can be harvested from different locations (e.g. nasoseptal or 
auricular cartlages) and various species (e.g. bovine or porcine), the biosynthetic and 
proliferative capacities of which are different.  Recently, chondrocytes isolated from 
human nasal septal cartilage were seeded on a processed porcine nasal septal 
cartilage 3D scaffold [281].  Cells successfully migrated into the matrix and 
synthesized collagen II and aggrecan, and the regenerated cartilage tissue retrieved 
the function and compressive strength comparable to its native counterpart up to 6 
weeks in in vitro culture [281].  However, the resulting compressive strength was far 
less than the articular cartilage.  Further, nasal septal chondrocytes have an 
ectodermal origin, while articular chondrocytes have a mesodermal origin, which 
might make articular chondrocytes a better source for articular cartilage engineering. 
Since a low number of autologous chondrocytes is available in a patient 
suffering from a cartilage defect, using allogeneic or xenogeneic sources appears to 
be reasonable.  Cartilage is considered to be an “immune privileged” tissue, due to 
the lack of blood vessels and lymphatics.  Furthermore, cartilage’s dense ECM 
theoretically limits adjacent immune cells from penetrating and detecting 
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chondrocytes’ antigens [322].  Moreover, immunosuppressive medications are 
usually used in patients prior to receiving any types of transplants [323].  Although a 
mild immune reaction has been reported in some patients, either chondral or 
osteochondral allografts have been successfully used in the clinic, without being 
rejected [323].  The application of isolated allogeneic chondrocytes would haves 
different outcome, requiring further investigation. 
  According to a recent study, this “immune privileged” notion about cartilage 
needs to be used with caution [324].  In this study self-assembled constructs formed 
from either allogeneic (leporine) or xenogeneic (bovine) chondrocytes were applied 
to fill artificial lesions in two different sites (patella and trochlea) of the rabbit knee.  
Neo-cartilage tissues generated by the xenogeneic chondrocytes strongly provoked 
both innate inflammatory and cell-mediated immune responses in the host, resulting 
in the rejection of the constructs.  The response was location-related in the case of 
allogeneic constructs, and limited to the joint (no systemic reaction).  While the 
immune response was provoked in the patellar defects, the regenerated tissues 
survived in trochlear ones [324].  It should be kept in mind, however, that this study 
suffered from some limitations, such as the small number of experimental animals 
(n=3, the least number that was statistically acceptable), and use of small-sized 
animal models (rabbit).  Therefore, further investigation is required to verify the 
results in different locations in larger animals, and ultimately in humans.  In future 
studies, however, the results of implanted allogeneic constructs in vivo studies should 
be interpreted with caution, considering that the location of explants and the results 
from one location may not be applicable to other locations.  The results of this study 
also highlight the beneficial effect of using decellularized tissues, and specifically 
CD particles as fillers to reduce the number of cells, to repair cartilage defects, since 
cells and cell components normally elicit immune reactions.  It is worth noting that 
creating any lesion in articular cartilage, either with or without using an implant, can 
potentially elicit an innate inflammatory reaction.  The rate and severity of this 
response depends on multiple factors such as surgical, local, and systemic conditions, 
as well as the host factors. 
As an alternative, MSC known to be potential substitutions for chondrocytes, 
although a similar controversy also seems to exist in the application of MSC derived 
from OA patients.  For instance, one observed that adipogenic and chondrogenic, but 
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not osteogenic, capacities were highly reduced in MSC exploited from patients 
suffering from advanced stages of OA [198], while in another study it was shown 
that, despite the lower number of MSC derived from OA patients, they still had the 
potential to be used in tissue regeneration processes [325]. It was also shown that the 
application of an ECM-derived scaffold made from hypertrophic cartilage for 
seeding MSC resulted in bone formation after implantation in a bone defect [326].  
These findings imply that MSC sources should be chosen carefully in achieving 
better results in cartilage tissue regeneration.  In this regards, MSC derived from 
synovium might be the best stem cells for cartilage tissue regeneration due to their 
high proliferation capacities, along with their potential to differentiate into 
chondrocytes, both of which appear to be age-independent [327], and, therefore, 
could probably be successfully used in elderly OA patients.  
 
 
3.7 CONCLUSION 
 
The present study found that CD was well integrated into cartilage constructs 
after only 14 days of in vitro culture, followed by 4 weeks of in vivo implantation, 
and that the CD supplement resulted in larger tissues having enhanced chondrogenic 
gene expression.  Specifically, our results demonstrate that CD is rapidly 
incorporated into the developing tissue construct (within 24 hours), and that after 2 
weeks of culture in vitro, followed by 4 weeks of implantation in vivo, the CD 
incorporation results in a matrix rich in GAG and collagen II.  Rapid repair is likely 
to be a necessary feature of future cartilage repair strategies, as this will reduce the 
period of time required for complete immobilization of the patient’s joints following 
surgery, as well as the period of time during which the joint is especially sensitive to 
unintended micro-trauma.  We propose that CD may provide a valid strategy to 
enhance the effectiveness of existing therapies, such as ACI, which rely solely on 
cells to regenerate functional cartilage tissue. 
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Chapter 4: Conclusions and Future 
Research Directions 
4.1 SUMMARY 
 
Articular cartilage defects, among which OA is the most common, are the 
leading causes of pain and physical disabilities worldwide [135].  The treatment and 
management of these injuries are troublesome for a large range of people, including 
patients, their families or carers, and health professionals.  Indeed, OA is considered 
to be a public health problem (Chapter 1).   
Since the cartilage’s self-repair capacity is limited, and it lacks nerve and pain 
fibres as an alarm system for disease, its injury progresses over time until surgical 
intervention usually becomes inevitable [36, 37].  Among various types of surgical 
treatments, cell-based therapies, such as ACI appear to have effective outcomes in 
traumatic joint injuries in young and healthy patients [260].  However, there are 
some drawbacks with this method.  Cell expansion, for example, which is normally 
performed on tissue culture plastic, causes chondrocytes to lose the clues that they 
had while living in cartilage ECM.  This results in chondrocytes taking fibroblast-
like phenotype, a process which is called dedifferentiation, and producing mostly 
fibrocartilage rather than articular cartilage matrix.  As a result, the lesion is filled 
mainly with fibrous rather than hyaline cartilage [203, 206].  To reverse the 
dedifferentiation, and help chondrocytes to restore their normal phenotype, some 
techniques have been developed.  Among the methods applied for chondrocyte 
redifferentiation, pellet culture is one of the most widely used, and was also chosen 
in our study, as was described in Chapters 2 and 3.  
Mature chondrocytes, as well as mesenchymal stem cells originating from 
various tissues but most commonly from bone marrow, are common types of cells 
normally recruited for cartilage tissue engineering.  Application of each group of 
these cells has its own advantages and drawbacks.  For example, while chondrocytes 
exist in limited numbers in a mature cartilage tissue, the normal culture medium 
currently used for MSC to chondrocyte differentiation needs to be improved to 
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inhibit hypertrophic changes in cells that ultimately result in bone rather than 
cartilage formation [215].  Human articular chondrocytes were used in this thesis 
project. 
The environment and microenvironment are other important factors for 
successful tissue engineering.  Native cartilage tissue has a hypoxic environment.  
The oxygen tension measured in human synovial fluid is 6.5-9.0% (50-70 mm Hg) 
[328].  From the superficial to the deep zone, the oxygen (O2) tension reduces from 
7% (53 mm Hg) to less than 1% (7.6 mm Hg) [329].  Similarly, chondrogenic 
differentiation and cartilage production can be best achieved in low oxygen tissue 
cultures [284].  For this reason, a low oxygen condition (2%) was chosen for our in 
vitro experiments. 
Either natural or synthetic scaffolds have been used in cartilage tissue 
engineering.  Recently, the application of decellularized tissues, or even organs, as 
naturally derived scaffold materials, has gained attraction worldwide and, in many 
instances, the outcomes have been promising, comparable with or even superior to 
synthetic scaffolds.  ECM is nature’s ultimate scaffold produced by the tissue’s 
resident cells, and provides structural support, facilitates cell-to-cell interactions, and 
contains biochemical ingredients, such as growth factors, all of which can accurately 
guide new cells to repopulate and regenerate the tissue [217].   Since cartilage is a 
tissue with only one type of cell and mostly consists of tissue matrix, the notion of 
applying decellularized tissue appears to be easily possible for cartilage tissue 
engineering.  However, it is the dense matrix that makes both cartilage 
decellularization and the following cell penetration and repopulation a real challenge.  
To address this problem, some research groups have attempted to reduce the 
thickness of the decellularized tissue, with the best results using processed tissue 
with a minimum thickness (10-30 µm) [34].  To further optimize cell infiltration 
through the ECM scaffold, we further reduced the dimension of the tissue to an 
average of 2 µm, and assessed the cartilage forming ability, both in the lab and in an 
ectopic site (subcutaneous) in immunodeficient mice.  The design and methods of 
our in vitro and in vivo experiments are explained in Chapters 2 and 3.  
The primary aim of this study was to optimize in vitro cartilage tissue 
production by expanded chondrocytes, through the incorporation of cartilage ECM-
derived scaffold material, and explore the ability of the in vitro constructs to produce 
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cartilage tissue in vivo in an ectopic mouse model.  Results from the in vitro study 
showed that after only 14 days of culture, CD supplementation resulted in larger 
pellets, with the CD particles well-integrated into cartilage constructs, as well as 
superior cartilage production evidenced by enhanced GAG production and 
chondrogenic gene expression.  Subcutaneous implantation of cartilage constructs 
with or without CD for 4 weeks demonstrated that constructs that lacked CD became 
even smaller and their remnant found far from the implantation site, and stained 
highly positive for collagen X.  On the other hand, CD-supplemented constructs were 
found in the implantation sites with the same size as at the time of implantation, and 
stained positive for GAG and collagen II.  These results and their analyses are 
discussed in chapters 2 and 3. 
 
4.2 CONCLUSIONS 
 
Replication of normal human articular cartilage through tissue engineering 
represents a significant challenge.  In currently approved cell therapies, such as ACI, 
a slurry of chondrocytes are transferred into the defect [260].  This cell suspension 
lacks mature cartilage matrix, and is extremely prone to trauma and even 
microtrauma, in the harsh environment of the articular joint.  Furthermore, cartilage 
normally matures over a long period of time [50].  Therefore, combining the cells 
with the mature donor tissue appears to be beneficial for successful repair of cartilage 
defects.   
In this thesis, a novel, enzyme-free method was described for producing 
decellularized cartilage particles, namely cartilage dusts (CD) that could be 
combined with chondrocytes to produce a composite tissue.  The resulting constructs 
were shown to have superior chondrogenic properties, and to be more stable over the 
4-week period of implantation in the mice, compared to cell-only pellets.  Indeed, 
cartilage microparticles (mainly 2 µm) could be prepared using a simple freeze-
drying and pulverization process.  Inclusion of these microparticles into chondrocyte 
constructs improved the total tissue volume and GAG production in vitro, and also 
the stability of the construct in an ectopic in vivo model.  The small particles were 
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well-integrated into the constructs and could be useful for future cartilage defect 
repair applications.   
The results showed could be readily self-assembled with chondrocytes.  It is 
likely that microscopic particles of the CD could be injected into a given defect site.  
This strategy could have many advantages.  In ACI or MACI, for example, the 
addition of GAG containing CD should enhance the mechanical strength of either the 
cell suspension or the newly formed repair tissue, since they are very fragile.  This 
could be a significant step forward, as current ACI or MACI therapies suffer from 
the considerable vulnerability of the initial repair tissue to trauma or micro-trauma 
[330].  Furthermore, compared to synthetic scaffolds, the resultant CD-containing 
mixture could easily take the shape of the complex defect geometry.  This strategy 
may enhance the outcomes of current therapies, like ACI.  The addition of CD to the 
cell suspension could temporarily provide mechanical support by the time the repair 
tissue is produced and matured enough to withstand the harsh environment of the 
articular cartilage.  Further research is required to assess the existing similarities and 
differences in larger animals, and ultimately in humans, to verify the findings in 
more detail. 
This thesis described a minimally aggressive method for articular cartilage 
decellularization.  GAG production was significantly enhanced in the group 
supplemented with CD, compared to the group without CD.  The result from gene 
expression assay showed upregulation of chondrogenic genes in differentiated 
groups, especially in the CD-supplemented pellets.  However, the genes related to 
fibroblastic and osteoblastic differentiations were also highly expressed.  Taken 
together, gene expression assay and antibody localization staining, along with the 
results of other studies regarding the drawbacks of using OA-affected chondrocytes 
suggest that using chondrocytes and CD derived from healthy xenogeneic or 
allogeneic donors for future studies seems to be more rationale. 
The regulatory pathways responsible for specific interactions between cells and 
decellularized scaffold materials still remain mostly unknown.  Despite this, scaffold 
derived from naturally occurring ECM appears to have the potential to provide a 
valuable guide for differentiating cells in vitro and in vivo, and at least could be used 
as biocompatible fillers that temporarily enhance the mechanical features of the 
fragile, initial repair tissue.  This could be beneficial in reducing the immobilization 
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period of the patient’s joint following joint repair.  It worth proposing that CD may 
provide a valid strategy to enhance the effectiveness of existing therapies, such as 
ACI, in which rely on cells alone to regenerate functional cartilage tissue.   
 
4.3 LIMITATIONS AND FUTURE RESEARCH DIRECTIONS 
 
Autologous cells or tissues would be preferred to be used for tissue engineering 
purpose compared to cells or tissues derived from xenogeneic or even allogeneic 
sources.  For this reason, the studies in this thesis used human articular cartilage for 
producing CD and cell exploitation.  The cartilage tissues were isolated from 
macroscopically healthy cartilage remnants in osteoarthritic joints, since OA is the 
main reason for open joint surgeries.  Further, the results would be more reliable to 
be used in the treatment of OA patients with tissues engineered from autologous 
cells.  However, the application of cells derived from OA affected joint is 
controversial, which are discussed in the Chapter 3.  There is evidence implying that 
these OA-affected chondrocytes have inferior functions compared to chondrocytes 
released from non-OA joints [299, 321], that appears to be compatible with some of 
the results mentioned in this thesis.  Chondrocytes derived from donors suffering 
from osteoporosis, or from other cartilage tissues in the body such as nose cartilage 
might worth considering in future experiments.  Using chondrocytes derived from 
nasal septal cartilage has some advantages over other sources of chondrocytes, such 
as articular, auricular, or costal cartilage;  it causes less donor site morbidity, access 
to the source tissue is easier, and small sized biopsies are required to retrieve 
sufficient number of cells [281, 331].  It could be also possible to use allogeneic or 
xenogeneic articular cartilage for CD production.  Future experiments, therefore, 
could be performed using, for example, bovine or porcine cartilage as an alternative 
source of donor CD, thus providing an essentially endless supply of matrix for 
human joint repair.  Immunogenicity might be a real concern using these sources, 
however, there are protocols to eliminate immunogenic antigens from donor tissues 
[278], and decellularized xenogeneic tissues have been successfully applied in the 
clinic [219].  Another concern in the application of non-autologous tissues is the 
possibility of pathogen transfer, which should be avoided through proper tissue 
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processing protocols.  In a recent study, porcine cartilage was applied successfully to 
repair a tracheal defect in rabbits that produced moderate inflammation and 
granulation after 2 weeks that substantially decreased after 8 weeks of in vivo 
implantation [332, 333].  
The cartilage dust used in the experiments of this thesis was prepared 
mechanically, without the application of enzymes that are routinely applied in 
current tissue decellularization protocols.  The method described in this thesis could 
effectively reduce the DNA content of the resultant CD just by producing 
microscopic particles, and subsequently washing the released DNA.  However, 
pulverization resulted in the reduction of GAG content of the produced CD 
compared to the original native tissue.  Changes usually happen either in the 
structure or in the composition of the original tissue with all of the current 
decellularization and sterilization methods.  Current protocols reduce the amount of 
either GAG or collagen in the processed tissue [26] which, in turn, could affect 
bioscaffold’s ability to support cells.  The optimal protocol would be the one with 
maximal effect in deleting pathogens and immunogens from the tissue, while having 
minimal effect on tissue structure and composition, and should be tissue-specific. 
The GAG amount measured in the collected media was almost two times 
higher in the CD-supplemented compared to the cell-only groups, indicating more 
GAG production in the former groups.  The release of GAG into the media during in 
vitro culture, however, is still a common problem in chondrogenesis experiments 
[287] , and results in the loss of produced GAG.  One reason for the release of GAG 
into the medium might be that the accumulation of other matrix components, for 
example, collagen type II or aggrecan happens later than the GAG production [287].  
Further, the formation of a cross-linked collagen II network, which is essential for 
the entrapment of the proteoglycan content of the cartilage matrix, needs more time 
to take place.  The loss of GAG could be addressed by using scaffolds or injecting 
the cells or a mixture of the cells and the CD into the target tissue. 
  A main function of the tiny particles of decellularized cartilage used in this 
thesis was to reinforce the cell suspension applied in ACI at the time the most 
mechanical support is needed.  However, CD could be quite versatile.  It could also 
be possible, for example, to simply inject a chondrocyte-CD suspension via a less 
aggressive method that is needle injection, into a defect.  The CD could also act as 
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filler by use of which the number of expanded cell for ACI can be diminished given 
that the mature articular cartilage is a very low-cell-density tissue. 
The aims of this thesis were to optimize the in vitro production of cartilage 
tissue with the CD, and to evaluate the incorporation of the CD particles into the de 
novo cartilage tissue both in in vitro and in in vivo.  The results showed that the CD 
could be well-integrated with the engineered tissue, and resulted in a more stable 
construct in the subcutaneous tissue at the back of the mice.  Although the in vivo 
condition used in this study is not comparable with the environment of an articular 
tissue, but could give a good insight about the benefits of using the CD in the 
cartilage constructs engineering.  Next experiments could be done in larger animals 
such as rabbit or sheep, after further optimization of the experiments performed in 
this thesis.  In future studies, the result of the application of the tissue engineered 
constructs could also be tested in different time points, for example, with the 
implantation of the constructs after shorter culture duration, or even after mixing the 
cells with the CD, to allow the tissue maturation happen in the body, or following a 
longer tissue cultivation with the implantation of the more mature construct into the 
body.  The more mature generated in vitro constructs could also be tested 
biomechanically to assess the effect of CD supplementation on their mechanical 
properties.  With relatively short culture duration both constructs (with and without 
CD) are highly cellular, and appear to have sub-optimal structure to bear the test.  
Longer in vitro duration should result in more mature tissues [334].  Preferably, 
cartilage constructs could form in vitro under dynamic culture conditions or, 
alternatively, be matured in vivo by early implantation in a joint to receive tissue 
specific biochemical and biomechanical signals in the native cartilage 
microenvironment. 
The in vitro culture condition (the formation of cell pellets, the medium, and 
the incubator conditions) used in this study is the gold standard in cartilage tissue 
engineering.  In general, chondrocytes’ microenvironment in vitro could still be 
improved to achieve better results.  The oxygen tension measured in human synovial 
fluid is quite low, and, in joint disorders this oxygen tension in synovial fluid 
decreases even further [335].  Further, articular cartilage is believed to have an acidic 
nature, in the healthy and diseased state.  Given that chondrocytes live in an 
avascular and hypoxic environment, anaerobic glycolysis is their major metabolic 
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pathway [39].  Thus, hyaline cartilage is characterized by an acidic pH [336].  pH 
values of 6.9 to 7.2 have been measured in healthy cartilage tissues [102, 104].  Even 
a small shift in extracellular pH can have a significant influence on cell function and 
matrix formation [337].  Further, the dependence of cartilage cells on glycolysis to 
produce energy imposes a further challenge to maintain intracellular pH [338].  So, 
perception of pH homeostasis and its challenging effect on matrix synthesis is of 
great importance, despite it having been seemingly overlooked within the literature 
[339].  Mimicking the native microenvironment of chondrocytes in the joint might 
improve cartilage production by these cells.  Furthermore, the assessment of 
chondrocytes survival and their cartilage production capacity in an environment as 
harsh as a diseased joint might give an insight into the probable outcome of 
regenerated tissue in the defect site after cell implantation.  Another issue worth 
considering is utilizing CD derived from different zonal regions of either human or 
xenogeneic tissues, as this would be expected to help regenerate the desired zonal 
nature of native cartilage tissue [99].  It was demonstrated by Amanatullah et al. that 
various zones of articular cartilage had distinct sets of gene expression that were 
compatible with their functional differences.  Aggrecan gene, for example, had a 9.1 
times higher expression in the middle zone, compared to superficial zone [340].  The 
greatest differences in gene expression pattern, as well as cellular functions, observed 
between the superficial and deep zones of articular cartilage [341].  
MSCs could be good substitutes for chondrocytes.  Despite the popularity and 
the obvious benefits of using chondrocytes for cartilage tissue engineering, the 
possibility of dedifferentiation and the limited expansion potential of chondrocytes, 
as well as morbidity in donor sites could be troublesome.  As a result, there is 
increasing interest in the employment of MSCs instead of chondrocytes [36, 323].  
They are rapidly becoming the preferred cells for both cell-based and scaffold-based 
tissue engineering because they can be relatively easily harvested in large numbers, 
are easy to expand in vitro to provide therapeutic cell quantities, and are capable of 
undergoing chondrogenic differentiation following in vitro expansion [342, 343].   
Furthermore, for the successful treatment of inflammatory and immune diseases, 
such as OA or rheumatoid arthritis (RA), MSCs may be a good cell source due to 
their anti-inflammatory and anti-immunogenic potential [18, 194, 323].  Various 
tissues other than bone marrow, such as adipose tissue, muscle, synovium, and dental 
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pulp can be a source of MSCs [195].  Sakaguchi et al. compared the chondrogenesis 
ability of human MSCs derived from different origins, including bone marrow, 
synovium, periosteum, skeletal muscle and adipose tissue and demonstrated that the 
highest chondrogenic potential belonged to MSCs derived from synovium, bone 
marrow and periosteum, respectively [344].  However, bone marrow-derived MSCs 
are thought to be preferred for cartilage repair applications due to their capacity to 
differentiate into cartilage, their quantitative availability, the minimally invasive 
methods available for obtaining them, as well as some evidence that shows that they 
preserve their differentiation potential while proliferating [345].  However, this 
uncertainty indicates that more research is needed to conclusively establish the best 
tissue of origin for MSCs for a particular application [17].  
In addition to tissue origin, factors such as the patient’s age and disease phase 
may have an influence on the potential and speed of replication of MSCs [17, 18].  
According to Murphy et al., MSCs in patients with advanced OA compared with 
MSCs in healthy donors have minimal proliferation and chondrogenic differentiation 
capacities, and show a tendency toward osteogenicity [198].  However, adding 
specified amounts of parathyroid hormone-related peptide (PTHrP) to the culture has 
been found to suppress the expression of collagen type X (indicators of osteogenesis) 
and also lowers the activity of alkaline phosphatase, resulting in the maintenance of 
cartilage matrix properties [199].  Co-culturing MSC and articular chondrocytes 
might also be beneficial in terms of the requirement for fewer chondrocytes, as well 
as reducing hypertrophy in MSC [59].  It has been known that secretion of the 
parathyroid hormone-related protein by articular chondrocytes prevents MSC from 
undergoing hypertrophic changes [346]. 
Despite remarkable progress in cartilage tissue engineering, further research is 
needed the achievement of a mature and functional tissue.  Application of 
decellularized native cartilage tissue is very promising as the matrix is produced by 
the resident cells, in the natural environment in the body.  Therefore, using ECM 
derived matrices, along with improving the culture conditions in vitro, could be a 
large step toward achieving cartilage tissue regeneration. 
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